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Foreword 
 
The journey that has culminated in this thesis has been rewarding and 
interesting.  I graduated from the University of York with a BA(Hons) in Social 
Policy.  Whilst working in public health in Bradford I completed an MSc in Health 
Services Research at the University of York.  My interest in the field of diabetes 
started when I undertook a year-long secondment to the Yorkshire and Humber 
Public Health Observatory, co-hosted by the Yorkshire and the Humber Strategic 
Health Authority and the University of York.  This involved developing data tools 
and resources to assist service improvement in diabetes care across England.  
Overtime the scope of this role developed to include national and international 
projects to explore and develop data on people with diabetes and the healthcare 
services they require.  Organisational changes, in particular, the move of the 
Public Health Observatories into Public Health England in 2013 meant that the 
scope for novel work and addressing research questions was restricted.  
Registering for a PhD gave me the chance to develop my research skills and 
pursue opportunities to use the large, routinely collated datasets, which I had 
become familiar with to focus on research questions.   
 
The initial prompt for the analyses presented in this thesis varies due to 
restriction on the use of NDA data in early years so I therefore had to be nimble 
and seek out other opportunities. The analysis of mortality among inpatients 
with diabetes presented in Chapter 3 arose following concerns raised by Dr 
Rowan Hillson, then National Clinical Director for Diabetes. Chapter 4 is the 
result of a project set up by NHS Diabetes to explore the potential to collect and 
analyse data on the characteristics and outcomes of people with diabetic foot 
disease.  Chapter 5 was a collaboration with Dr Bob Young and colleagues in 
Salford to explore a dataset that had been accumulated over a decade.  Chapter 
6 follows conversations with Dr Roger Gadsby and Dr Bob Young about the lack of 
evidence around the NICE recommendation for all people with diabetes to 
undergo nine clinical checks, known as care processes, on at least an annual 
basis as part of a review of the on-going management of diabetes and associated 
risks.  Chapters 7 and 8 followed on from direct conversations with my 
supervisors and other colleagues around the emerging evidence of poor long-
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term outcomes for people diagnosed with Type 2 diabetes in early adulthood 
with a particular reference to differences by ethnic group.   
 
In all the analyses presented, I refined the research questions following 
conversations with clinical and other colleagues, and with approval of my 
supervisors. I explored the scope of the available datasets to address the 
question and developed specific hypotheses. I defined the data required and 
specified the statistical methods. I undertook the data preparation, cleaning and 
analysis. Initial findings were shared with co-authors and supervisors and, if 
required, the analysis was refined. Where the work has been published in peer 
reviewed journals I drafted the initial paper and co-ordinated editing and 
amendments with co-authors. I also managed the submission process to the 
journal, amended the paper following review in consultation with co-authors and 
drafted the response to reviewer comments. The chapters that have not yet 
been published in a peer-reviewed journal were fully drafted by myself and 
revised following comments from my supervisors. I am currently preparing some 
of the later chapters for submission to peer reviewed journals.    
 
Since October of 2019, I have been fortunate to receive research funding from 
Diabetes UK to continue to explore the further use of the National Diabetes 
Audit to address research questions.  Given the size of the National Diabetes 
Audit, this is a wonderful opportunity. This post will allow me the opportunity to 
build on the skills and knowledge I acquired during my PhD studies and to 
continue conversations and exploratory analysis to shed further light (and raise 
more questions) on outcomes of people with diabetes in a real world setting.  It 
will also, hopefully, develop understanding of the scope and potential of the 
dataset and facilitate its use within the research community.   
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Summary 
 
Current diabetes management is strongly influenced by a number of landmark 
trials that have highlighted the role of intensive blood glucose management and 
reduction of cardiovascular risk factors in reducing diabetic complications and 
ultimately the long term risk of mortality.  This thesis collates contemporary 
data on aspects of diabetes care and diabetes outcomes in England and Wales 
and discusses the implications.  
 
Analysis of data for inpatient stays across England shows that people with 
diabetes are disproportionately likely to die during their hospital admission 
compared to people without diabetes of a similar age.  This can partly, but not 
wholly, be explained by a higher proportion of emergency admissions and 
reported co-morbidities.  The additional risk of death associated with diabetes 
was significantly greater in smaller hospitals.   
 
Having diabetes increases the risk of macro and micro vascular disease which can 
lead to poor foot health.  Analysis of data collected over a twelve year period on 
all people presenting with diabetic foot ulcers in Salford, England highlights the 
significant morbidity and mortality in this group.  Only 45% of ulcers had healed 
within 90 days and almost a fifth of people die within two years of presentation.  
The lack of nationally collated data on foot health meant that there was a 
significant gap in the knowledge of outcomes among people with diabetic foot 
disease.  Designing a dataset and collection process, which was tested in 23 units 
across England, has led to the establishment of the National Diabetes Footcare 
Audit which now reports annually.   
 
In an analysis of National Diabetes Audit data the recording of care processes 
and associated interaction with healthcare professionals appears to be 
associated with a lower risk of mortality than among people with diabetes for 
whom such care is not recorded.   
 
Type 2 diabetes is increasingly being diagnosed at younger ages including early 
adulthood.  Analysis of the National Diabetes Audit shows that people diagnosed 
with Type 2 diabetes aged between 20 and 39 years old have higher (age 
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adjusted) mortality than those diagnosed in later life.  This is partly explained 
by higher prevalence of poorer cardiovascular risk factors but the additional 
relative risk remains statistically and clinically significant.  The analysis also 
suggests that the increased relative mortality risk associated with diabetes in 
early onset Type 2 diabetes is present for White and Black ethnic groups but not 
for South Asians.  Type 1 diabetes has traditionally been considered to result in a 
higher risk of cardiovascular events and death than Type 2 diabetes.  However, if 
diagnosed in early adulthood medium term mortality risk is similar in people 
with Type 1 and Type 2 diabetes.   
 
The work presented here provides an insight into the current outcomes of people 
with diabetes in England.  It also illustrates the value of routinely collated 
datasets in building knowledge and identifies some of the challenges this type of 
analysis faces.   
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Diabetes in the UK 
Diabetes mellitus is defined by chronic hyperglycaemia due to an absolute or 
relative lack of insulin.  The lack of insulin is due to the dysfunction or 
destruction of beta cells and therefore an inability to produce enough insulin for 
the body’s needs.  There are two main types of diabetes.  Type 1 diabetes is an 
auto-immune disease resulting in the destruction of the insulin producing beta 
cells of the islets of Langerhans in the pancreas.  This results in absolute insulin 
deficiency and is fatal without the regular administration of insulin to meet the 
body’s requirements.  Type 2 diabetes occurs when the pancreas is unable to 
produce sufficient insulin for the body’s requirements.  This may be the result of 
impaired insulin secretion and/or resistance to the action of insulin.    
 
The symptoms of diabetes include frequent urination, especially at night, being 
thirsty, fatigue, unintentional weight loss, genital itching and thrush, cuts and 
wounds taking longer to heal and blurred vision.  Type 1 diabetes is relatively 
fast in onset and, if untreated, diabetic ketoacidosis will develop and may be 
fatal.  Type 2 diabetes is more gradual in onset and may be asymptomatic for 
many years.   
 
Diagnostic criteria 
There are currently three diagnostic criteria for diabetes and only one criteria 
needs to be met for a diagnosis to be made [1].  The criteria are 
• A fasting plasma glucose of 7.0 mmol/l or greater 
• A two hour post-load plasma glucose of 11.1 mmol/l or greater  
• A HbA1c of 48 mmol/mol or greater 
 
Current guidelines in the UK suggest that in an asymptomatic person the 
diagnosis of diabetes should never be based on a single raised HbA1c or fasting 
plasma glucose level and at least one further abnormal result should be obtained 
prior to formal diagnosis.  In a symptomatic person a diagnosis of diabetes can 
be based on a single raised HbA1c or fasting plasma glucose measurement 
although it should be noted that severe hyperglycaemia in people with acute 
infection, trauma or circulatory stress may be transitory [2]. 
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The World Health Organisation recommends the use of fasting plasma glucose to 
diagnose diabetes but acknowledges that HbA1c may also be used [3].  The 
European Association for the Study of Diabetes recommends that diagnosis of 
diabetes is made using either a fasting plasma glucose or HbA1c [4].  Similarly 
the American Diabetes Association recommends the use of HbA1c for the 
diagnosis of diabetes [5].  The use of HbA1c as a diagnostic test is practically 
simpler and does not require either a fasting prior to taking a blood sample or a 
glucose challenge with associated two hour wait for final blood samples.  It can 
therefore be conducted anytime of the day and during acute illness such as after 
a myocardial infarction.  
 
Diabetes Prevalence 
In England there are two main sources of data on the population prevalence of 
diagnosed diabetes.  The Quality and Outcomes Framework is a set of quality 
assessment indicators linked to financial incentives for general practices [6].  As 
part of this general practices are required to maintain a register of all people 
aged 17 years and older with a diagnosis of diabetes (except gestational 
diabetes).  These data show that the number of adults registered with a general 
practice in England with a diagnosis of diabetes has increased from 2,455,937 in 
2011 [7] to 3,319,266 in 2019 [8].  The National Diabetes Audit also provides 
information on the current prevalence of diabetes in England and Wales and 
shows a similar increase in the prevalence of diagnosed diabetes over the same 
time period with 3,398,470 people of all ages being identified across England 
and Wales using data from primary care and specialist diabetes services (see 
Figure 1.1).   
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Figure 1.1 Prevalence of diabetes recorded by the National Diabetes Audit for 
England and Wales 
 
 
As the physiological mechanism underlying Type 1 diabetes is distinct from that 
related to type 2 diabetes there are significant differences in the epidemiology 
of the two most common types of diabetes.  The age profile of people with type 
1 diabetes is somewhat similar to that found in the general population (see 
Figure 1.2a).  The prevalence of Type 1 diabetes is also higher amongst males 
than females across all ages.  There is minimal evidence of an association 
between the prevalence of Type 1 diabetes and social deprivation.  In the 
2012/13 audit cohort 20.5% of people with Type 1 diabetes lived in the most 
deprived fifth of neighbourhoods compared to 18.9% living in the least deprived 
areas [9].   
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Figure 1.2a: Age and sex profile of people with Type 1 diabetes from the 
National Diabetes Audit, 2012/13 
 
 
The epidemiology of Type 2 diabetes shows that risk is not evenly distributed 
across the population.  The age profile of those diagnosed with Type 2 diabetes 
and included in the National Diabetes Audit for England and Wales show that the 
proportion of people diagnosed under the age of 40 years is low.  The prevalence 
of Type 2 diabetes increases steadily up to the age of 80 years old.  Declines in 
the prevalence of Type 2 diabetes after the age of 80 years can be attributed to 
the adverse impact of Type 2 diabetes on mortality and reduced life expectancy 
amongst those with the condition.  Another explanation for a lower prevalence 
in type 2 diabetes above 80 years is that more people will be losing weight due 
other illness causing unintentional weight loss.  This epidemiological phenomena 
is known as reverse causality.  The prevalence of Type 2 diabetes is also higher 
amongst males than female at all ages (see Figure 1.2b). 
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Figure 1.2b: Age and sex profile of people with Type 2 diabetes from the 
National Diabetes Audit, 2012/13 
 
 
Role of adiposity 
The risk of developing Type 2 diabetes increases as body mass index increases.  
Data from the 2018 Health Survey for England reports that the prevalence of 
total (diagnosed and undiagnosed) diabetes was 12% among obese adults (body 
mass index of 30kg/m2 or greater) compared to 7% in those that are overweight 
(body mass index 25-29.9kg/m2) and 5% in adults who were not overweight (body 
mass index less than 25kg/m2) [10].  The distribution of body fat is associated 
with the risk of Type 2 diabetes with central obesity (measured by waist 
circumference) being associated with a greater prevalence.  In the 2018 Health 
Survey for England 14% of men and 10% of women with a very high waist 
circumference (more than 102 cm and more than 88 cm respectively) had either 
diagnosed or undiagnosed diabetes. This compared to 6% of men and 3% of 
women with high waist circumferences (94-102cm and 80-88cm respectively) and 
5% of men and 4% of women with a desirable waist circumference (less than 
94cm and less than 80cm respectively) [10]1.   
 
 
1 Although these data relate to total diabetes prevalence (all types including Type 1 diabetes and 
others not associated with obesity the fact that, at a population level, the vast majority of 
adults with diabetes have Type 2 diabetes means that the associations shown here will be driven 
by the association between Type 2 diabetes and obesity as the number of people with other 
types will be very small. 
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Ethnic Variations in diabetes prevalence 
 
Variation in the risk of Type 2 diabetes by ethnic group is well documented.  In a 
recent analysis of the UK biobank [11] the ethnic differences in diabetes risk 
were easily apparent with multiple fold higher rates in South Asians, being 
highest in those of Bangladeshi origin, and lowest in those from India with risk 
being intermediate in those of Pakistani origin.  Of further note, it was clear 
that Type 2 diabetes was more common in the male sex in each of these 
ethnicities than their female counterparts in age, body mass index and social 
class standardised analyses.  There was also evidence for higher diabetes risk in 
those from Black ethnic groups but whether risk was greater in Chinese was less 
clear.  These UK Biobank data are somewhat selected but even so, they allow 
good matching for usual confounders such as social class and body mass index 
and as a result they nicely demonstrate the variance in diabetes risks over and 
above such confounders. 
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Figure 1.3: (taken from Ferguson et al) Prevalence of diabetes mellitus by 
ethnicity and sex standardised for age, socioeconomic status, BMI, and lifestyle 
factors 
 
 
The association between body mass index and risk of Type 2 diabetes varies by 
ethnicity. People from South Asian ethnic groups typically have a risk of Type 2 
diabetes with a body mass index of 24 kg/m2 that is equivalent to their peers 
from White ethnic groups with a body mass index of 30kg/m2.  Those from Black 
ethnic groups show a similar risk at a body mass index of approximately 27kg/m2 
[12].  
 
Role of Social deprivation 
There is a strong social deprivation gradient in the prevalence of Type 2 
diabetes.  24.7% of the 1,681,331 people with Type 2 diabetes included in the 
2012/12 National Diabetes Audit cohort lived in the most deprived fifth of areas 
compared to only 15.5% in the least deprived.  The association between social 
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deprivation and established risk factors for Type 2 diabetes is not straight 
forward.  People living in the more deprived areas are more likely to be from 
South Asian and black ethnic groups and are also more likely to be overweight or 
obese.  On the other hand the age structure of areas with high levels of social 
deprivation is younger than among the more affluent areas. As a consequence it 
is not possible to attribute all the variation in prevalence of Type 2 diabetes to 
underlying social deprivation.  However, the fact that psychological stress has 
been shown to be a factor in the onset of Type 2 diabetes [13] means that living 
in an area of high social deprivation and the associated stress means that an 
independent association cannot be ruled out.   
 
Epidemiological considerations and future projections about prevalence 
The fast onset of clinical symptoms in Type 1 diabetes means that it in 
epidemiological studies it is assumed that all those with the condition will be 
diagnosed.  However, the more gradual nature of the development of Type 2 
diabetes and the lack of life threatening symptoms mean that many people meet 
the criteria for the diagnosis of diabetes but are unaware of their condition.  In 
2008/09 it was estimated that 27% of people with diabetes had not yet been 
diagnosed [14].  Increasing awareness of the benefits of earlier diagnosis, and 
therefore management, of Type 2 diabetes amongst the clinical professions and 
the general public alongside specific public health interventions such as Health 
Checks for people aged 40 years and older has led to a reduction in the 
estimated proportion of people that are undiagnosed.  In March 2019 3,319,266 
people (6.9%) people aged 17 years and older included in general practice 
registers had a diagnosis of diabetes [8].  This compares to estimates based on 
trends in population characteristics (age and ethnic group structure) and obesity 
as measured by the Health Survey for England that 8.6% of adults aged 16 years 
and older meet the diagnostic criteria for diabetes.  Demographic changes as the 
population structure ages and, in particular amongst those ethnic groups that 
have a higher prevalence of diabetes mean that by 2035 it is estimated that the 
total prevalence of diabetes among adults in England will increase to 9.7% [15].   
 
Despite clear definitions of Type 1 and Type 2 diabetes and differing 
physiological causes the distinction between types of diabetes in clinical settings 
and epidemiological research is not always clearly and accurately recorded.   
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Different types of diabetes 
There is also an increasing understanding and recognition of hybrid forms of 
diabetes (slow evolving immune mediated diabetes in adults and ketosis prone 
Type 2 diabetes) and other specific forms of diabetes including monogenic 
diabetes.  Following changes to the definitions used to identify people with 
diabetes in the Quality and Outcomes Framework (a general practice quality 
based financial incentive scheme) a programme of work was undertaken to 
review the classification and coding of diabetes within clinical systems.  As part 
of this a systematic review of existing literature was undertaken.  It found that 
the misclassification of types of diabetes had potential consequences for 
treatment regimens and risk management of people with diabetes.  Although 
studies included in the review were too heterogeneous to allow for results to be 
combined a common theme was that younger people were more likely to 
experience miscoding of type of diabetes [16].  An audit tool was developed to 
identify people with diagnosed diabetes where the type of diabetes may be 
misclassified based on other routinely recorded data.  Testing and validation of 
this tool found significant levels of misclassification of types of diabetes 
recorded in clinical systems.  In further analysis of 54,088 patients across nine 
general practices in Leicester 13.5% of people with a diagnosis of diabetes were 
identified as potentially being misclassified.  After further examination of 
clinical records the percentage of those deemed to be misclassified fell to 7.4% 
[17].  This suggests that whilst there is a clear theoretical distinction between 
the types of diabetes the reality of clinical practice and routine data recording 
mean that data obtained from these sources may not always reflect the true 
underlying pathology.  It also highlights the importance of cross validating data 
taken from routine clinical care with other variables recorded and undertaking 
appropriate sensitivity analyses around type of diabetes where the results are 
likely to be contingent on the grouping of diabetes types.   
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Complications of diabetes 
 
Cardiovascular complications 
People with diabetes are at greater risk of developing cardiovascular disease 
than those without hyperglycaemia. For those with Type 2 diabetes this risk is 
roughly double that in non-diabetes patients and begins to accumulate well 
before diabetes is diagnosed.  
 
Heart failure occurs when the ability of the ventricles to fill or empty is 
reduced.  It may follow damage to the muscle following an ischaemic event or 
be attributable to diabetic cardiomyopathy.  Stroke is the term used to describe 
an event when the supply of blood is cut off.  An ischemic stroke occurs when a 
cerebral blood vessel is obstructed whilst a haemorrhagic stroke is the result of a 
leak or bleed from a cerebral blood vessel.  Other complications include 
peripheral vascular disease, linked to narrowing of the vessels that supply the 
legs.   
 
Analysis from the National Diabetes Audit shows that in 2017/18 people with 
Type 1 diabetes were 3.8 times more likely to have a hospital admission for a 
myocardial infarction, 3.2 times more likely to have a stroke and 4.2 times more 
likely to be admitted to hospital for heart failure than their peers without 
diabetes.  The comparable figures for people with Type 2 (and other types) 
diabetes were 2.0 for myocardial infarction, 1.8 for stroke and 2.4 for heart 
failure. Further analysis shows that the age is the strongest predictor of 
cardiovascular risk, followed by HbA1c and systolic blood pressure measured in 
the six years prior to the potential event [18].   
 
Microvascular complications  
Hyperglycaemia increases the risk of microvascular disease. This may affect all 
body systems and blood flow is restricted by the narrowing of small blood 
vessels.  Diabetic retinopathy occurs when the retina is damaged and micro 
aneurysms form.  In more advanced disease new blood vessels are formed in the 
eye which may burst and cause bleeding which obstructs vision.  In 2013, 5.4% of 
registrations for severe sight loss and 6.3% of sight impairment registrations in 
England and Wales were attributed to diabetic retinopathy and maculopathy 
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[19].  Kidney disease is a common microvascular complication of diabetes.  As 
the glomeruli become damaged protein will leak from the blood into urine.  
Narrowing of the renal artery may also contribute to declining kidney function.  
The risk of end stage kidney disease (requiring dialysis or transplantation) is 17 
fold higher for people with Type 1 diabetes and 3.6 greater for people with Type 
2 diabetes compared to those without diabetes [18].  As the nervous system 
relies on the circulation system (and vice versa), the narrowing of small blood 
vessels can also lead to neuropathy.  This may affect all areas of the body 
including peripheral limbs and the digestive system.   
 
Risk for complications and effects of glucose reduction  
 
Figure 1.4: Meta-analysis of effects of HbA1c reduction in microvascular 
outcomes in an individual participant meta-analysis of major landmark trials 
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Hyperglycaemia increases the risk of developing macro and microvascular 
disease.  As a result people with diabetes are more likely than their peers to 
experience cardiovascular events, develop chronic kidney disease, sight loss due 
to retinopathy and maculopathy and have poor foot health leading to ulcers [20].  
There is now strong evidence trial that reducing glucose levels per se lowers 
risks of the above complications although admittedly the findings for neuropathy 
from clinical trials is not as clear cut as one would imagine.  In terms of 
cardiovascular disease (CVD), whilst results from several intensive glucose trials 
were somewhat disappointing for lowering of CVD risk, the pooling of such 
studies suggested around a 15% lower risk for coronary heart disease from around 
a 0.9% reduction in HbA1c levels. However, this meta-analysis also suggested no 
effect of such intensive glucose reduction on all-cause mortality [21], at least by 
treatment available at that time.  Indeed, it should be remembered that such 
studies were done in an era before much of the newer drugs now proven to 
lower CVD were being used.  More recently, a meta-analysis on microvascular 
events, showed intensive glucose reduction by around the same amount of 0.9% 
over a period of 5 years in major trials lowered kidney outcomes by 20%, and eye 
outcomes by 13% but no clear evidence for an effect on nerve outcomes (Figure 
1.4, taken from Zoungas et al) [22].  
 
Foot ulcers 
People with diabetes have a much elevated risk of developing foot ulcers.  There 
are a number of physiological factors that combine to create this elevated risk.  
Macrovascular damage to the main arteries in the lower body can reduce the 
flow of oxygenated blood to the lower leg and feet.  This may be compounded 
by microvascular damage to blood vessels in the lower leg and foot.  Neuropathy 
in the lower limb extremities can result in the loss of sensation (and neuropathic 
pain).  This loss of sensation results in a greater risk of trauma and for the injury 
to go unnoticed for a substantial period of time.  Diabetic foot ulcers are prone 
to infection which hinders healing.  It is estimated that the prevalence of 
diabetic foot disease is 2-2.5% of those with diagnosed diabetes [23].  As a result 
of diabetic foot disease people with diabetes are approximately 23 times more 
likely to have a lower limb amputation than their peers without diabetes [24].  
The medium to long term prognosis of people with diabetic foot disease is poor 
with only three fifths of people surviving for five years [23].   
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Mortality risks 
Diabetes is associated with an increased risk of mortality.  It is estimated that 
Type 1 diabetes results in a life expectancy reduction of 11 years for men and 13 
years of life lost for women [25].  The loss of life expectancy associated with a 
diagnosis of Type 2 diabetes varies by age, sex and social deprivation with 
greater losses amongst younger adults, those living in deprived areas and 
females [26].  In 2017 there were 6040 deaths where the primary cause of death 
was diabetes in England and Wales [27] but comparisons of mortality rates for 
the same year in people included in the National Diabetes Audit suggest 32,000 
more deaths than would be expected based on mortality patterns amongst their 
peers [28].  This indicates that the vast majority of additional mortality risk 
experienced by people with diabetes is attributable to the greater risk of 
cardiovascular, microvascular and other complications rather than severe hypo 
and hyperglycaemic events. 
 
The evidence for improving diabetes related outcomes 
The Randomised Controlled Trials Diabetes Control and Complications in people 
with Type 1 diabetes (DCCT) [29] and UK Prospective Diabetes Study in Type 2 
diabetes (UKPDS) [30] established that hyperglycaemia and, for type 2, raised 
blood pressure are pathogenic factors for diabetic retinopathy.  The long-term 
observational follow-up studies of their cohorts EDIC for DCCT [31] and UKPDS 
10yr for UKPDS [32] also generated evidence that hyperglycaemia and raised 
blood pressure might influence the incidence of further microvascular and 
cardiovascular complications.  These epidemiological follow-up observations 
following closure of the randomised controlled provided some evidence of a 
‘legacy effect’ of metformin on cardiovascular disease whereby the patients in 
the original metformin intervention group had fewer cardiovascular events and 
deaths despite post trial convergence of glucose levels.  Another randomised 
trial (VADT) in Type 2 diabetes [33] found that lower glucose levels (6.9% vs 
8.4%) were associated with fewer cardiovascular events only when there was 
clear separation of HbA1c between the control and intervention groups. In VADT 
there was no effect on mortality but in the ACCORD Type 2 diabetes study [34] 
the intervention group in which an HbA1c of below 42mmol/mol was targeted, 
myocardial infarction events reduced but mortality increased. Overall, from the 
intensive glucose lowering trials, there was evidence for a benefit on non-fatal 
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cardiovascular disease but no improvement in total mortality.  Accordingly, 
concerns persist about the strength of the evidence, particularly in respect of 
severe disabling or life-threatening long-term outcomes for optimal glucose 
levels in both Type 1 [35] and Type 2 diabetes [36]. Also, many studies have 
excluded heart failure which is emerging as one of the most prevalent and 
harmful cardiovascular complication of diabetes [37]. Furthermore, debate is 
ongoing about whether the hazards of glucose lowering treatment outweighs its 
benefits when levels are lowered closer to normal using conventional treatments 
[36] and about the use of surrogate markers of treatment efficacy, such as 
HbA1c [38].  
 
Classes of drugs shown to lower outcomes 
 
More recently, two newer classes of drugs used in diabetes have been shown to 
lower cardiovascular and related outcomes.  These are important results since 
established classes of drugs have either relatively modest evidence for such 
benefits (i.e. metformin) or lack such trial evidence (sulphonylureas) or have 
neutral effects (DPP-4 inhibitor classes).  These two newer classes include the 
sodium-glucose cotransporter-2 inhibitor (SGLT2i) and the Glucagon-Like Peptide 
1 Receptor Agonists (GLP-1RA) classes.  The former SGLT2i class works by 
enhancing the urinary excretion of glucose at lower glucose levels, whereas the 
latter class work as incretin hormones to enhance insulin release, though they 
also help aid weight loss.  As shown in a recent meta-analysis [39] (Figures 1.5a-
d), class lower hard renal outcomes most strongly, followed by heart failure, 
with a lesser reduction in major adverse cardiovascular outcomes (MACE), driven 
mostly by a reduction in CVD death.  The benefits on MACE seem to be restricted 
to those with existing ASCVD whereas other benefits were evident in all groups 
of patients recruited into the trials.  The benefits seem to occur independently 
of baseline HbA1c levels and of any changes in HbA1c.  The current best thinking 
is that this class of drugs leads to haemodynamic benefits that lessen nephron/ 
glomerular stress (and so sizeable reductions in renal outcomes) and lead to 
reduced cardiac workload by reducing both cardiac pre- and afterload, and so 
are associated with less heart failure and subsequently fewer less cardiovascular 
deaths.  However, many other potential mechanisms remain possible and this is 
the subject of considerable ongoing work.  
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Figure 1.5a. Risk of MACE by SGLTi trials by baseline ASCVD or multiple risk 
factors   
 
Figure 1.5b Heart hospitalisation and CVD death by Meta-analysis of SGLTi trials 
by baseline ASCVD or multiple risk factors   
 
 
Figure 1.5c Heart hospitalisation and CVD death by Meta-analysis of SGLTi trials 
by baseline history of heart failure   
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Figure 1.5d Risk for renal outcomes in SGLTi trials by baseline ASCVD or multiple 
risk factors 
 
Figures 1.5a-d from Zelniker et al. Meta-analysis of different outcomes (MACE, 
Heart failure/ CVD death or renal disease) from SGLTi trials by baseline 
characteristics.   
 
For GLP-1RA, a separate meta-analysis [40] (Figures 1.6a-b from Kristensen et 
al, see below) showed these agents also lower MACE, CVD death, total mortality 
as well as a hint to lowering incident heart failure.  The benefits on hard renal 
outcomes seemed more variable. Furthermore, benefits on MACE seemed to 
extend beyond those with prior ASCVD to those with evidence of disease but no 
prior MI or stroke.  The benefits of GLP-1RA, like those of SGLT2i, also seemed to 
occur independently of baseline HbA1c.   
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Figure 1.6a Risk of MACE and each of its components. Figure from Kristensen et 
al 
 
Three-component MACE consisted of cardiovascular death, myocardial infarction, and stroke. 
NNTs are calculated over an estimated median follow-up of 3·2 years. MACE=major adverse 
cardiovascular events. GLP-1=glucagon-like peptide-1. NNT=number needed to treat. *For 
PIONEER 6, data for fatal and non-fatal myocardial infarction and stroke were not available, so 
numbers and estimates refer to non-fatal myocardial infarction and non-fatal stroke exclusively. 
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Figure 1.6b: All-cause mortality, hospital admission for heart failure, and kidney 
outcomes.  Figure from Kristensen et al. 
 
 
The consequence of the results of these outcome trials is that new guidelines for 
the use of these agents have been published by Diabetes- and cardiology-led 
guidelines, as recently published [4,41]. Both have now accepted that these two 
classes of drugs can be used independently of baseline glycaemia.  There 
remains ongoing debate whether baseline metformin is necessary in treatment 
naïve patients who are recommended for these therapies, as well as what class 
of drug should be recommended and in what circumstance.  Equally, there is 
uncertainty and debate on the use of these drugs to patients without existing 
cardiovascular disease, renal disease or heart failure.    
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The current clinical management of people with diabetes is based around 
guidance issued by NICE [42,43].  It focuses on identifying and reducing the risk 
of developing diabetic complications by reducing hyperglycaemia and minimising 
established cardiovascular risk factors through lifestyle and pharmaceutical 
interventions.  There is now clear evidence for substantial benefits of lipid-
lowering and blood pressure management in the care of people with diabetes 
[21].  With regards to blood pressure, many patients with diabetes have 
hypertension, and the Angiotensin converting enzyme (ACE) inhibitors and 
Angiotensin receptor blockers (ARB) classes of drugs have been shown to have 
specific benefits in lessening proteinuria or its progression.  Blood pressure 
targets have also been tightened over the decades so that control of blood 
pressure has improved in many countries in people with diabetes.  Certainly, 
most people with diabetes should have systolic blood pressure levels targeted to 
below 140 mmHg and arguably, many younger patients should seek levels below 
130 mmHg.  With respect to cholesterol, these targets have also been reduced 
over the years and many patients with Type 2 diabetes are now on statins. 
Indeed, it appears as if CVD risk reduction is more greatly reduced by blood 
pressure and lipid lowering than it is by glucose reduction per se, at least over 
the course of 5 years.  By contrast, the evidence base for aspirin in primary 
prevention in diabetes and in general has weakened, though it remains critical in 
secondary prevention.  Hence, NICE recommendations correctly focus on 
comprehensive risk factor management to prevent future complications.  
 
Database Research in Diabetes: Real World Evidence 
Over the last ten years there has been an expansion in the use of large datasets 
based information routinely recorded in the course of clinical care to explore the 
epidemiology of diabetes.  This has predominately been made possible by the 
use of electronic systems to record clinical information at the point of care 
delivery [44].   
 
The data included in real world datasets is recorded as part of clinical practice.  
This has both positive and negative implications.  Firstly, it provides the ability 
to access large scale data without the considerable time and costs associated 
with specific research data collections.  It also is less likely to have significant 
sample bias.  The populations recruited to randomised control trials are rarely 
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representative of the full patient population for which they seek to provide 
evidence for clinical practice [44,45].  By collating data from the full range of 
people under the care of a clinical service the data represents the greater 
variation in patient characteristics, especially those with multi-morbidity and 
other more complex needs.  On a less positive note the completeness and quality 
of the data may not be as high as would be expected within a similar cohort 
where data was primarily collected for research purposes.  The definitions used 
will be defined by the primary use of the data which may include performance 
monitoring and financial arrangements and may be subject to change over time.  
The data collected will also be subject to potential differences in clinical 
behaviour between individual clinicians and organisations. 
 
The National Diabetes Audit in England and Wales 
The National Diabetes Audit (NDA) was established in 2003 to assess the quality 
of, and variation in, diabetes clinical care and outcomes in order to inform 
service improvement across England and Wales.  It addresses five specific 
questions  
• Is everyone with diabetes diagnosed and recorded on a practice diabetes 
register? 
• What percentage of people registered with diabetes received the nine 
National Institute of Health and Care Excellence (NICE) key processes of 
diabetes care? 
• What percentage of people register with diabetes achieved NICE defined 
treatment targets for glucose control, blood pressure and blood 
cholesterol? 
• What percentage of people registered with diabetes are offered and 
attend a structured education course? 
• For people with registered diabetes what are the rates of acute and long 
term complications (disease outcomes)?  
 
The NDA is managed by NHS Digital in partnership with Diabetes UK.  It is one of 
more than 30 National Clinical Audits commissioned by the Healthcare Quality 
Improvement Partnership on behalf of NHS England and the Welsh Government. 
In England the legal basis for the NDA collection and use is (since 2017) provided 
by a ‘direction’ under section 254 of the 2012 Health and Social Care Act from 
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NHS England to NHS Digital; in Wales it is granted section 251 approval by CAG 
(which applied in England up to 2016). The NDA has, under these regulations the 
information governance permissions for access to the dataset to answer specific 
research questions.   
 
The National Diabetes Audit collates data on every person registered at 
participating health providers with a coded electronic record of diagnosed 
diabetes mellitus.  From 2017/18 people with Non-Diabetic Hyperglycaemia have 
been added.  Women with gestational diabetes are not included.  Participation 
in the audit is open to all primary and specialist care healthcare providers in 
England and Wales with data extracted from electronic patient records.  
Between 2003/04 and 2016/17 participation for primary care was through an opt 
in process.  Some electronic clinical systems provided the facility to 
automatically create and submit the required data extract.  From 2017/18 
onwards participation in the audit was automatically undertaken by primary care 
electronic clinical systems with the option to opt out of data collection process 
either as a general practice or as an individual with diabetes.  Participation of 
specialist secondary care health service providers is by submission of an extract 
from their electronic clinical system.  The data collation process is managed and 
undertaken by NHS Digital which is the national provider of data and IT systems 
for the NHS.   
 
Between the audit years 2003/04 and 2018/19 a total of 4,714,395 people were 
included in at least one NDA data collection.  Between 1st January 2005 and 31st 
December 2018 there were 1,028,560 deaths recorded among people who were 
recorded in one or more audit data collection round.  Further demographic 
details of the people included in the cohort are listed in Table 1.1.   
 
There is an annual data collection for the NDA.  Each data collection extracts 
data for a 15 month period running from the beginning of January in the first 
year to the end of March the next year.  For example, the data collection for 
2017/18 collects data recorded between 1st January 2017 and 31st March 2018.  
Until 2016-17 only the latest recorded data and measurements in each audit 
period were included in the dataset but since then all values have been 
extracted e.g. all instances of HbA1c or blood pressure measurement.  
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Demographic data (date of birth, sex, date of diabetes diagnosis, ethnic group) 
from across data collection periods has been combined to minimise missing data 
and ascertain the most likely true value for each individual.  Where an individual 
has been included in the NDA in multiple years and there is variation in the 
demographic data provided for different time periods the most commonly 
reported value is taken to be the most likely to be accurate.  If no single value 
has been provided more frequently, the latest value is taken to be the most 
accurate.   
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Table 1.1: Characteristics of people included one or more data collection of 
the NDA, 2003/04 to 2018/19 
 
Type 1 
diabetes 
Type 2 
diabetes 
Other types 
of diabetes 
Type of diabetes 
not stated 
Sex 
 
Male 204,292  2,307,554  31,025  45,659  
 
Female 157,040  1,852,282  38,417  70,216  
 
Not stated 15  57  12  7,826  
Year of birth 
 
Pre 1930 15,410  487,067  5,425  29,891  
 
1930-1939 29,148  891,576  7,551  18,774  
 
1940-1949 39,267  1,031,893  10,263  14,077  
 
1950-1959 47,883  852,641  10,764  10,631  
 
1960-1969 60,713  583,137  10,929  10,247  
 
1970-1979 51,549  237,367  11,319  12,655  
 
1980-1989 48,421  64,148  9,017  12,866  
 
1990-1999 42,465  10,523  3,063  3,735  
 
2000 onwards 26,461  1,167  1,019  611  
 
Not stated 30  374  104  10,214  
Year of diagnosis 
 
Pre 1970 17,691  8,215  137  755  
 
1970-1979 26,728  16,808  193  961  
 
1980-1989 44,892  91,025  485  3,296  
 
1990-1999 84,822  500,418  1,949  13,539  
 
2000-2009 111,930  1,815,958  10,499  26,749  
 
2010 onwards 71,287  1,700,626  48,455  8,338  
 
Not stated 3,997  26,843  7,736  70,063  
Ethnic group 
 
White 267,386  2,645,756  39,843  50,942  
 
Mixed 4,084  37,837  750  864  
 
Asian 18,688  443,174  7,254  6,152  
 
Black 12,472  169,337  2,716  3,204  
 
Other 6,724  86,356  1,593  1,987  
 
Not stated 51,993  777,433  17,298  60,552  
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Table 1.1 sets out the categories of data collected for each audit period of the 
NDA.  Demographic data is collected for each individual included in the audit for 
each time period.  This provides date of birth, sex, date of diabetes diagnosis, 
type of diabetes, ethnic group and lower super output area of home address (to 
identify geographical location and allocate social deprivation score).  The care 
process data comprises the date and result of HbA1c, blood pressure, total 
serum cholesterol, urinary albumin/creatinine ratio, serum creatinine, body 
mass index measurements, smoking status and foot examination. Eye screening 
data is held in the screening programme management systems that have hitherto 
been unable to link to the other core data; it is hoped that this will become 
possible for 2019/20 data. 
 
The use of insulin pumps and the reasons for starting to use them is provided by 
a specific data collection undertaken by specialist healthcare providers for those 
under their care.  The co-morbidities of learning difficulties and severe mental 
illness are identified through the recording of a diagnosis in the general practice 
record.  From 2017/18 onwards the NDA has collected data on all prescriptions 
issued for glucose lowering agents, anti-hypertensive drugs and statins. 
 
Table 1.2: Data collected for each audit period 
  2
0
0
3
/
0
4
 
2
0
0
4
/
0
5
 
2
0
0
5
/
0
6
 
2
0
0
6
/
0
7
 
2
0
0
7
/
0
8
 
2
0
0
8
/
0
9
 
2
0
0
9
/
1
0
 
2
0
1
0
/
1
1
 
2
0
1
1
/
1
2
 
2
0
1
2
/
1
3
 
2
0
1
3
/
1
4
 
2
0
1
4
/
1
5
 
2
0
1
5
/
1
6
 
2
0
1
6
/
1
7
 
2
0
1
7
/
1
8
 
2
0
1
8
/
1
9
 
Demographic data ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Care processes  ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Hospital admissions ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Co-morbidity of learning 
difficulties 
            ✓ ✓ ✓ ✓ 
Co-morbidity of severe 
mental illness 
            ✓ ✓ ✓ ✓ 
Use of insulin pump 
including reason for use of 
device 
            ✓ ✓ ✓ ✓ 
Glucose lowering drugs, 
statins and anti-
hypertensive drugs 
              ✓ ✓ 
Date and cause of death ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
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The NDA has an established links to the Hospital Episode Statistics (HES) for 
England and Patient Episode Database for Wales (PEDW) to identify all hospital 
admissions that occur in people included in one or more audit collection process.  
The cohort is also linked to death registrations compiled for England and Wales 
by the Office for National Statistics.  This provides the date and cause of death 
for all people who have been included in one or more NDA data collection.  
Monitoring of year on year recording of care processes and intermediate clinical 
outcomes (HbA1c, blood pressure and total cholesterol) has shown that between 
2003/04 and 2006/07 there was a significant rise in the proportion of people 
meeting the then recommended target of a HbA1c of 58mmol/mol or less from 
56.3% to 62.6%.  However, this proportion had only increased marginally to 63.3% 
in 2010/11 and 65.0% in 2017/18.  Similar patterns were shown in the proportion 
of people achieving the recommended targets for blood pressure and 
cholesterol.  This suggests that whilst there were documented substantial 
improvements in the attainment of recommended treatment targets in the early 
years of the NDA this improvement appears to have reached a plateau [46].   
 
Data from the 2012/13 NDA cohort was used to identify how the current ‘real 
world’ outcomes of people with newly diagnosed Type 1 diabetes compare with 
the landmark Epidemiology of Diabetes Interventions and Complications (EDIC) 
study intervention and control groups.  This found that a broadly similar cohort 
from the NDA in 2012/13 had a mean HbA1c of 72mmol/mol compared to 
56mmol/mol and 76 mmol/mol in the intensive treatment and control arms of 
the EDIC study.  A cohort of people with Type 2 diabetes matching the criteria 
for the UK Prospective Diabetes Study (UKPDS) was also identified.  This group 
had a mean HbA1c of 57 mmol/mol compared to 53 mmol/mol in the intensive 
treatment  and 63 mmol/mol in the conventional treatment arms of the UKPDS.  
These comparisons provide an insight into how real world clinical outcomes 
compare to key trials and highlight that whilst considerable improvements have 
been seen in the intermediate clinical outcomes for those with Type 2 diabetes 
further progress is required to improve outcomes and close the gap between 
what can be shown in research settings and real world outcomes in people with 
Type 1 diabetes [47]. 
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Variations in outcomes by ethnic group have been documented using data from 
the NDA.  After adjusting for demographic characteristics (age, sex, social 
deprivation), type and duration of diabetes, cardiovascular risk factors (HbA1v, 
blood pressure, cholesterol, body mass index) and hospital admissions people 
from South Asian and Black ethnic groups had lower short term mortality than 
those from white ethnic groups (Odds ratio 0.533 95% CI 0.504-0.563 and 0.529 
95% CI 0.487-0.574 respectively) [48]. 
 
Each year a report detailing the demographic characteristics and intermediate 
clinical outcomes of people with diabetes are produced by the NDA team.  
Further reports are produced which examine hospital admissions for 
cardiovascular and other diabetes related complications and mortality.  A full 
list of the NDA reports can be found at https://digital.nhs.uk/data-and-
information/publications/statistical/national-diabetes-audit. 
 
The strength of this cohort is that it is representative of the vast majority of 
people with diabetes and in 2017/18 included over 95% of the people registered 
with diagnosed diabetes across England and Wales.  The significant size of the 
cohort means that it is possible to identify statistically significant variation 
amongst sub-groups that make up a small proportion of the population with 
diabetes, for example, those from minority ethnic groups and those diagnosed 
with Type 2 diabetes in early adulthood. 
 
The primary weakness of the data is that it is drawn from information recorded 
as part of routine clinical care rather than specific data collected for research 
purposes.  This means that there may be more variation in the interpretation 
and use of clinical codes than would be found amongst data obtained through a 
specific data collection process.  The rate of missing data is also likely to be 
higher.  The fact that the data collated for each audit period used until 2017 
only the latest recorded measurement in the period means that in the past some 
detail of the variation in clinical measures has not captured.  The breadth of the 
data collected is more limited than many research cohorts but recent additions, 
such as the inclusion of drug data and identification of learning difficulties and 
severe mental illness, mean that the cohort will have the scope to address 
broader questions in the future.   
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Other data sets  
There are of course other national datasets. Most notable for their contribution 
to contemporary diabetes epidemiology are those from Scotland, Sweden and 
Denmark as well work from USA.  There are also notable papers from other 
sources.  Recent reviews have collated mortality and other statistics from 
multiple national cohorts, with a notable recent review paper [49] showing 
declines in mortality in diabetes over time but other secular changes by age of 
patients with diabetes (Figures 1.7a to 1.7b). 
 
Figure 1.7a: Trends in rates of all-cause mortality among populations with 
diagnosed type 2 diabetes. Taken from Gregg et al 
 
42 
 
Figure 1.7b: Trends in major diabetes complications by age among people with 
diagnosed diabetes in the USA. Taken from Gregg et al 
 
 
As current demographic and lifestyle trends mean that the prevalence of 
diabetes is likely to rise with an estimated 4.8 million people (9.5% of the 
population) having diabetes (either diagnosed or undiagnosed) by 2030 [14,50]. It 
is estimated that 10% of National Health Service expenditure can be attributed 
to diabetes and its complications and this proportion will rise to 17% by 2035 
[51].  Understanding the characteristics and outcomes of people with diabetes is 
vital to improving clinical care and reducing morbidity and mortality.  Using 
routinely collected data offers an efficient way to scrutinise data on large 
cohorts of people in a ‘real world’ setting.   
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Chapter 2: Context and Methods 
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Context of the range of work undertaken in this PhD 
 
The work detailed in this thesis represents a long journey that was not always 
linear and was shaped by changing NHS structures, national developments in 
data governance and shifting perceptions around the use of large datasets.  In 
2006 I was fortunate to start work at the Yorkshire and Humber Public Health 
Observatory on their emerging national programme of work on diabetes.  The 
Yorkshire and Humber Public Health Observatory was jointly hosted by the then 
Yorkshire and Humber Strategic Health Authority and the University of York. This 
organisational position meant that I had access to NHS based databases and was 
working in an environment that encouraged innovative approaches to data 
analysis and presentation.  During this time, I expanded my technical knowledge 
and developed an understanding of diabetes through close working relationships 
with clinical colleagues.  The 2012 Health and Social Care Act resulted in a 
fundamental reorganisation of the NHS England.  As part of this in April 2013 the 
work of Public Health Observatories was subsumed into the newly established 
civil service organisation, Public Health England.   
 
After realising that research was where my heart was and that the shift of the 
Public Health Observatories into Public Health England would change the focus 
of my employed work and offer fewer opportunities to innovate and explore data 
I registered for a PhD under the supervision of Professor Naveed Sattar in 2013.  
As well as providing a more formal basis for my research endeavours this offered 
the opportunity to undertake interesting projects that would not have reached 
the required priority to become part of the formal work programme of Public 
Health England.  The original plan was to utilise the National Diabetes Audit to 
explore variation in outcomes in people with diabetes by ethnic group.  Formal 
data access requests were lodged within a couple of months of registration.  
However, this coincided with a sudden and fundamental change in the 
interpretation and application of the information governance rules for large 
scale health datasets.  The fact that patient level data on hospital admissions 
had been made available to private companies for commercial analysis became 
public knowledge.  At a similar time public and professional support for the large 
scale care data programme to expand centralised data collection of routine 
clinical records to all activity within general practice was withdrawn 
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(https://www.bbc.co.uk/news/health-26259101).  This led to the Inquiry into 
the Handling of NHS Patient Data by the Health and Social Care Select 
Committee in 2014 
(https://www.parliament.uk/business/committees/committees-a-z/commons-
select/health-committee/inquiries/parliament-2010/handling-nhs-patient-
data/).  These events led to a very cautious culture around sharing patient level 
data across NHS data analysis organisations and an effective ban on establishing 
new data sharing arrangements.  As a result, no agreement around access to the 
NDA data could be reached until August 2017.  The work presented in Chapters 
6, 7 and 8 was undertaken whilst on an honorary contract with NHS Digital 
between September and December 2017.     
 
The National Diabetes Audit for England and Wales 
The National Diabetes Audit (NDA) for England and Wales was established in 2003 
to assess the quality of, and variation in, diabetes clinical care and outcomes in 
order to inform service improvement across England and Wales.  It addresses five 
specific questions  
• Is everyone with diabetes diagnosed and recorded on a practice diabetes 
register? 
• What percentage of people registered with diabetes received the nine 
National Institute of Health and Care Excellence (NICE) key processes of 
diabetes care? 
What percentage of people register with diabetes achieved NICE defined 
treatment targets for glucose control, blood pressure and total blood 
cholesterol? 
• What percentage of people registered with diabetes are offered and 
attend a structured education course? 
• For people with registered diabetes what are the rates of acute and long-
term complications (disease outcomes)?  
 
Every patient with a diagnosis of diabetes (except gestational diabetes) is 
eligible to be included in the NDA.  Data on patient demographic characteristics, 
the care processes received and the results of care processes that are routinely 
recorded in clinical systems are extracted and compiled.  The first data 
collection covered the time period 1st January 2003 to 31st March 2004 and 
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included 250,400 people with diagnosed diabetes registered with 3,886 general 
practices.  The 2017/18 data collection included information on 3,398,469 
people from 7,435 general practices and 114 specialist healthcare providers.   
Since its inception the NDA has linked the information provided by primary care 
and specialist healthcare providers to routinely compiled data sources on 
hospital admissions (Hospital Episode Statistics for England and Patient Episode 
Database for Wales).  Analysis has identified the occurrences of hospital 
admission for cardiovascular disease (myocardial infarction, heart failure, stroke 
and angina), end stage kidney failure, lower limb amputation and diabetic 
ketoacidosis.  From 2010/11 data linkages have also been made to death 
registrations compiled by the Office for National Statistics (see below for further 
detail).  In 2015/16 data collected by the NDA was extended to include an 
indication of individuals who had a comorbid diagnosis of severe mental illness or 
learning disabilities.  Specialist healthcare providers were also invited to provide 
the details of people using an insulin pump.   
 
One of the significant limitations of the NDA has been the lack of data on drugs 
prescribed to individuals with diabetes.  From 2017/18 onwards the scope of the 
audit has expanded to include prescription data for glucose lowering drugs, anti-
hypertensive medications and statins.  Whilst the primary purpose of this data is 
no assess the extent to which people with diabetes are receiving the care set out 
in NICE guidelines, the inclusion of this information significantly extends the 
scope and nature of the research questions that the NDA can address.  It also 
gives scope to validate the information provide on types of diabetes.   
 
Over the 16 years that the NDA has been in operation there have been a number 
of developments to the data collation mechanisms and the information 
governance structure for processing the data.  There have been advances in the 
automation of data collection from electronic clinical systems initially through 
establishing bulk data extractions with system suppliers and latterly by using the 
General Practice Extrication Service (https://digital.nhs.uk/services/general-
practice-extraction-service) which has facilitated the wider participation in the 
audit and increasing coverage of people with diabetes.   
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The analysis of the NDA data presented in Chapters 6, 7 and 8 is limited to 
patients receiving care from a healthcare provider in England.  At the time of 
undertaking this work, the legal basis for holding the patient level data of 
individuals under the care of Welsh healthcare providers was uncertain.   
The details above refer to the Core NDA, which now provides an annually 
updated dataset. It was recognised that it provided a wealth of information but 
that its full potential was not being realised and that there were many aspects 
of diabetes care and outcomes that were not covered by the existing 
methodology and dataset. In 2008, NHS Diabetes undertook a large scale national 
consultation with the diabetes community to identify areas to develop the NDA.  
The resulting programme of work included establishing and piloting a national 
diabetes inpatient audit, an audit of pregnancy in women with diabetes and an 
audit of care and outcomes for people with diabetic foot disease.  Steering 
groups were established to identify the audit questions, define a dataset to 
answer the questions, design and test a data collection and analysis plan.   
 
The NDA is managed by NHS Digital in collaboration with Diabetes UK under 
contract from NHS England and the Welsh Assembly.  It is part of the National 
Clinical Audit and Patient Outcomes Programme that is commissioned by the 
Healthcare Quality Improvement Partnership.   
 
Hospital Episode Statistics 
Since 1989 the NHS has been compiling data on hospital activity including 
inpatient and outpatient care in the form of Hospital Episode Statistics (HES) 
(https://digital.nhs.uk/data-and-information/data-tools-and-services/data-
services/hospital-episode-statistics).  The primary purpose of this data is to 
inform payments to healthcare providers but it is also a valuable data resource 
for public health analysis and research.  Access to HES was via pre-existing 
organisational data sharing agreements between Yorkshire and Humber Public 
Health Observatory/Public Health England and NHS Digital (including predecessor 
organisations).  This facilitated access to the full set of variables within the 
patient level dataset subject to rules on the presentation of small numbers to 
protect individual confidentiality.   
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Chapter 3 is an analysis of HES to investigate inpatient mortality among people 
with diagnosed diabetes.  A strength of this work is the factor that it was able to 
include every NHS hospital admission in England over a two-year period.  This 
census (rather than sample) approach ensures the data analysis is representative 
and results are obtained with a high degree of statistical significance.  However, 
the use of HES data as a stand-alone dataset has some limitations.  Other 
measures of hospital mortality compiled by NHS Digital and its predecessor 
organisations link HES data to death registrations to identify any deaths within a 
specified period of discharge from hospital (https://digital.nhs.uk/data-and-
information/publications/ci-hub/summary-hospital-level-mortality-indicator-
shmi, Strengths and weaknesses of hospital standardised mortality ratios, BMJ 
2011; 342 https://doi.org/10.1136/bmj.c7116).  This provides a more patient 
centred and holistic view of hospital outcomes.  The analysis presented in 
Chapter 3 would have been greatly improved by taking a similar approach.  
Unfortunately, the prevailing information governance climate at the time (see 
above) meant that it was not possible to obtain the necessary approvals to 
establish a new data linkage.  Another potential imitation of using HES to 
consider outcomes for people with diabetes is the reliance on discharge coding 
to identify the clinical reason for the hospital stay and any contributing co-
morbidities.  At the end of each episode of hospital care (a period of care 
provided by a single hospital consultant) clinical teams produce a discharge 
summary.  This, alongside other clinical notes if required, is used by teams of 
clinical coders to allocate ICD-10 codes for the primary and up to 12 secondary 
diagnoses for the hospital stay. An analysis of a specific cohort of the NDA (i.e. 
people known to have diagnosed diabetes) linked to HES data showed that in 
2007/08 a significant proportion of people with diabetes did not have the 
condition identified as a co-morbidity in discharge coding for their hospital stay 
[52].  However, those people with diagnosed diabetes who did not have a 
diagnosis of diabetes recorded within the record for their hospital admission had 
similar lengths of stay and re-admissions rates rather than the substantially 
elevated use of hospital services shown amongst those with diabetes included in 
their discharge coded conditions.  This suggests that whilst the coding of 
diabetes as a co-morbidity in HES was not complete at this time it was 
reasonably accurately identifying those in whom co-morbid diabetes was having 
a detrimental effect on their inpatient stay. 
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Death registrations 
The Office for National Statistics compiles a database of all deaths registered in 
England and Wales.  This includes demographic characteristics of the deceased 
and the date, location of death and cause of death.  Cause of death is classified 
using the International Classification of Diseases version 10 (ICD-10) 
(https://www.who.int/classifications/icd/icdonlineversions/en/).  The 
information provided on the death certificate by the doctor certifying death is 
categorised using an automated coding system, which gives one underlying cause 
of death and up to nine secondary causes 
(https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarri
ages/deaths/methodologies/userguidetomortalitystatisticsjuly2017).  As is 
common practice, all analyses presented in this thesis are based on the 
underlying cause of death.  
  
Statistical methods 
The subsequent chapters of this thesis report the results of a number of 
statistical analyses and use a variety of statistical tests and models.   
 
In order to test an association between two categorical variables Pearson’s chi-
squared test (often referred to simply as chi-squared test) is used.  This is a 
commonly used test to identify is there is a statistically significant difference 
between the observed and expected frequencies of two variables using a 
contingency table.  The calculation identified the expected number of cases that 
would occur in each combination of variables if they were evenly distributed 
across the categories (the null hypothesis).  These values are compared to the 
actual distribution of variables and the resulting values are compared to the chi-
squared distribution to identify statistical significance.   
 
The statistical difference between two continuous variables can be assessed 
using the Student’s t-test.  This test assumes that the two variables being 
compared follow a continuous distribution with a known mean.  Different 
calculations are used depending on whether the variation of the two variables is 
considered to be the same or not.  Where the relationship between a categorical 
variable with more than two categories and a continuous variable is considered a 
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group of calculations called Analysis of Variance or ANOVA are used.  They are an 
extension of the t-test. 
 
The two statistical tests listed above facilitate the comparison of two variables 
to identify statistically significant associations and differences.  However, 
epidemiological analyses often require an understanding of how multiple 
potential explanatory variables are associated with a specific outcome.  This 
requires statistical models that calculate multiple associations at the same time 
to be used.  Logistic regression is a statistical model that estimates the 
probability of a binary event occurring.  Categorical and continuous variables can 
be used to explain variation in the probability of the event occurring.  A logistic 
regression model calculates the logarithm of the odds of the specific event 
occurring for each category of any categorical variables included in the model.  
The logarithm of the odds associated with a change of a single unit in a 
continuous variable is also computed.  These values can be used to provide the 
odds ratio (and associated confidence intervals) for each value within a 
categorical variable and a single unit of a continuous variable [53].   
 
Whilst logistic regression can be used to investigate the probability of an event 
happening or not it does not take account of the fact that events may take place 
over a period of time and an event taking place in the short term has different 
implications to an event that occurs some time further in the future.  For 
example, if a cohort of people is followed up for a period of several years and 
the outcome of interest is death it would not be appropriate to give equal 
weight to a death that occurred a month after the start of the follow up period 
as to a death that may have occurred many years after initial data collection.  A 
set of statistical techniques, called survival analysis, can be used to assess the 
probabilities of a binary outcome based on multiple categorical and/or 
continuous variables.  The specific models presented in later chapters are Cox 
proportional hazard models.  This method is based on Breslow’s estimate of the 
baseline hazard function.  The model output includes hazard ratios associated 
with the outcome variable for each category of continuous variables and or each 
unit change of a continuous variable.   
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The statistical analyses presented in Chapters 3, 4 and 5 were undertaken in 
SPSS (https://www.ibm.com/uk-en/analytics/spss-statistics-software).  SAS 
(https://www.sas.com/en_gb/home.html) was used to undertaken the survival 
analysis presented in Chapters 6, 7 and 8.   
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Chapter 3: Mortality among inpatients with diabetes 
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Introduction 
 
In England 3.32 million adults had diagnosed diabetes in 2019 and total diabetes 
prevalence is expected to rise to 4.68 million by 2030 [8,14].  It is understood 
that diabetes results in higher mortality with those with Type 1 diabetes having 
an age standardised relative risk of dying of 2.35 and those with Type 2 diabetes 
being 1.36 times more likely to die than the general population [55].  People 
with diabetes are also more likely to be admitted to hospital, stay in for longer 
and be re-admitted as an emergency [52,56,57].  A diagnosis of diabetes and/or 
hyperglycaemia has been associated with poorer outcomes from hospital 
admissions for cardiac conditions [58–60].  However, there is little understanding 
of hospital mortality among patients with diabetes across the full spectrum of 
secondary and tertiary care.   
 
There is regular monitoring of hospital mortality by the NHS and private data 
analysis organisations to identify local variation and any outlier hospital trusts 
that may have exceptional mortality rates.  Although this monitoring provides 
data for sub-categories of admissions, the identification of diabetes is limited to 
patients where diabetes was the primary reason for admission.  Of the 15.0% of 
hospital beds occupied by people with diabetes in only 9.0% (representing 1.4% 
of hospital beds) was the patient admitted for diabetes specific reasons [61]. 
These diabetes specific admissions predominately comprise diabetic emergencies 
and are therefore skewed towards a minority of hospital admissions among 
people with diabetes with an over representation of younger patients and those 
with Type 1 diabetes.  This study has therefore examined hospital mortality 
among hospital admissions in patients with recorded diabetes.  It seeks to 
identify whether there is an additional risk of mortality after adjustment for 
case-mix among hospital admissions in patients with recorded diabetes, the vast 
majority of whom were admitted for non-diabetic reasons, and to identify the 
extent of any trust level variation which may be attributable to service delivery 
using a two year census of hospital admissions.  
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Methods 
An extract of every hospital admission to an English hospital between 1st April 
2010 and 31st March 2012 where the patient was less than 80 years old on 
admission was taken from Hospital Episode Statistics, a database that records 
every hospital admission funded by the National Health Service in England.  
Admissions were identified as relating to patients with diabetes if a code for 
diabetes (ICD-10 E10-E14) was included as a primary or secondary diagnosis.  The 
primary and secondary diagnosis codes for the hospital admission were searched 
for a number of co-morbidities.  These were used to calculate a modified 
Charlson index (see Table 3.1 for definitions and scoring) [62,63]. Deprivation 
was measured using the Indices of Multiple Deprivation 2010 based on the 
patient’s home address [64]. Method of admission was classified as elective, 
emergency or a transfer from another hospital trust.  All admissions were 
classified into Healthcare Resource Group (HRGs) version 4 chapters [65].  
 
 
Table 3.1: Modified Charlson score 
Co-morbidity ICD-10 codes identified in 
any diagnosis field 
Score 
Myocardial infarction  I21-I22 1 
Congestive heart failure I50 1 
Peripheral vascular disease I73.9, I71 1 
Cerebrovascular disease I60-I69 1 
Dementia F00-F03 1 
Chronic pulmonary disease J40-J47 1 
Connective tissue disease M30-M36, M05-M07, M10-M14 1 
Ulcer disease K25-K28 1 
Mild liver disease K70, K73, K74 1 
Hemiplegia G81, G82 2 
Moderate or severe renal disease N03-N16, N18-N19, N25 2 
Any tumour C00-C76 2 
Leukemia or lymphoma C81-C96 2 
Moderate or severe liver disease K72, I85 3 
Metastatis solid tumour C77-C80 6 
AIDS B20-B24 6 
 
  
55 
 
All regular hospital admissions (e.g. for chemotherapy treatments or dialysis) 
were excluded to remove bias resulting from repeats hospital admissions that 
relate to a specific treatment regimen and admissions relating to obstetrics (HRG 
chapter N) were excluded as they have the potential to obscure findings for 
women of child bearing age.   
 
Statistical analysis  
Differences in the characteristics of admission in patients with diabetes 
compared to those without diabetes were identified and the statistical 
significance of differences in proportions was tested using chi-squared tests.  A 
binary logistic regression model containing all admissions with diabetes recorded 
was created.  Death at the end of the hospital admissions was the dependent 
variable and age, sex, deprivation quintile, method of admission, modified 
Charlson score, HRG chapter and type of provider trust were included as 
explanatory variables.  The resultant equation was used to calculate the odds of 
death for each admission which was converted into the probability of death.  
The probability of death for each admission with diabetes was summed for each 
provider trust (one or more NHS hospitals administered under the same 
management structure) to give the expected number of deaths.  The observed 
number of admissions ending in death was divided by the expected number of 
admissions ending in death to give standardised mortality ratios comparing 
mortality among their admissions in patients with a diagnosis of diabetes to all 
admissions with diabetes included in the analysis for each hospital trust.  This 
gave a measure of relative mortality compared to all admissions with diabetes 
recorded included in the analysis. Confidence intervals for the standardised 
mortality ratios were calculated using the Byar’s method [66].  A separate model 
was created for admissions without diabetes to investigate whether the 
influence of case mix differed between admissions with and without a diagnosis 
of diabetes and to create a measure of relative mortality for all admissions 
without diabetes in the cohort. 
 
The extent to which variation in mortality in admissions among patients with 
diabetes reflected patterns of general hospital mortality was investigated with 
comparisons with general measures of hospital mortality.  The relationship 
between trust level mortality ratios for admissions with diabetes standardised to 
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all admissions with diabetes included in the analysis and the similar standardised 
mortality ratio for admissions without diabetes from this analysis, the Summary 
Hospital level Mortality Indicator (SHMI) produced by the NHS Information Centre 
and Hospital Mortality Standardised Ratio (HMSR) produced by Dr Foster Research 
Ltd was explored using Pearson’s correlation co-efficient and linear regression 
models [67,68]. 
 
To assess the impact of diabetes in different specialities a separate binary 
logistic regression model was created that included admissions with and without 
diabetes for each HRG chapter.  The dependent variable was whether the 
admissions ended in death and explanatory variables were age, sex, method of 
admission, modified Charlson score, type of hospital and whether the patient 
had a diagnosis of diabetes.  The odds ratios associated with diabetes were 
converted to relative risks using the formula set out by Zhang and Yu [69].  
These relative risks were used to calculate the number of additional deaths seen 
in patients with diabetes compared to those without diabetes by HRG chapter 
after standardisation for case mix in the two year period.   
 
Each provider trust included in the analysis was classed as an acute teaching 
trust, a large acute trust, a medium acute trust or a small acute trust [70].  A 
binary logistic regression model was created with death as the dependent 
variable and whether the admission had diabetes recorded, age at the start of 
the admission, sex, method of admission, modified Charlson score, HRG chapter 
and type of trust as explanatory variables for each group of trusts to identify 
whether the adjusted odds of mortality associated with diabetes being recorded 
differed by the type of provider.  To identify the additional risk of dying 
experienced in admissions among patients with diabetes compared to those 
without diabetes binary logistic regression models with death as the dependent 
variable were created for each provider trust.  These models included whether 
the admission had diabetes recorded, age at the start of the admission, sex, 
method of admission, modified Charlson score, HRG chapter and type of trust as 
explanatory variables.  The resultant odds ratios were converted to relative risks 
[69].  
 
All analyses were undertaken in IBM SPSS 20.   
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Results 
 
Between 1st April 2010 and 31stMarch 2012 there were 10,169,003 hospital 
admissions to 146 provider trusts that met the inclusion criteria. Of these 
1,142,830 (11.2%) had diabetes recorded.  Emergency admissions accounted for 
a greater proportion of admissions where there was a diagnosis of diabetes 
(75.8% vs 72.0% in those without diabetes, chi-squared=9573.602, df=2, 
p<0.005).  Compared to those without diabetes, admissions among patients with 
a diagnosis of diabetes were more likely to be for HRG E (cardiac surgery and 
primary cardiac conditions), HRG K (endocrine and metabolic system) and HRG L 
(urinary system and male reproductive system), HRG D (Respiratory system) and 
HRG b (Eyes and periorbita) (chi-squared=465816.962, df=18, p<0.005).  There 
were 169,999 deaths in hospital of which 36,662 (21.5%) were in admissions with 
diabetes recorded.  Adjustment for age, sex, method of admission, HRG chapter 
and type of hospital trust reduced the crude odds ratio of dying from 2.207 (95% 
CI 2.182-2.233) to 1.137 (95% CI 1.123 – 1.151) (-2 log likelihood=308633.493, 
df=26, p<0.005).  Adding the modified Charlson score to the case-mix 
adjustment further reduced the odds ratio to 1.065 (95% CI 1.052-1.079) (-2 log 
likelihood =1293894.81, df=31, p<0.005).  This equates to a 6.32% greater risk of 
dying for admissions among patients with diabetes than would have been 
expected in similar admissions without diabetes recorded (2,316 more deaths 
over two years); alternatively, it equals 1.4% of all deaths in all admissions (with 
and without diabetes). 
 
The results of the regression models exploring the different odds of mortality 
associated with the case mix factors in admissions among patients with diabetes 
recorded and separately among those without diabetes are shown in Table 3.2.  
Lower additional risks of death in admissions among patients with diabetes 
recorded compared to those without diabetes include older age and emergency 
admission or transfer from another trust.  After adjustment for age, sex, method 
of admission, HRG chapter and co-morbidities there were no coherent 
deprivation gradients in the odds of death among admissions in patients with 
diabetes or in those without diabetes recorded (see Table 3.2, third and sixth 
columns of data).   
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Table 3.2: Results of regression models for admissions with diabetes and 
those without diabetes   
 Admissions without diabetes recorded Admissions with diabetes recorded 
Adjusting 
for age, 
sex, 
method of 
admission 
reason for 
admission 
and type of 
trust 
Odds ratio 
 (95% CI) 
Adjusting for 
age, sex, 
method of 
admission 
reason for 
admission, 
type of trust 
and co-
morbidities 
 
Odds ratio 
(95%CI) 
Adjusting for 
age, sex, 
method of 
admission 
reason for 
admission, 
type of trust, 
co-
morbidities 
and 
deprivation 
 
Odds ratio 
(95%CI) 
Adjusting 
for age, 
sex, 
method of 
admission 
reason for 
admission 
and type 
of trust 
Odds ratio 
 (95% CI) 
Adjusting 
for age, 
sex, 
method of 
admission 
reason for 
admission, 
type of 
trust and 
co-
morbiditie
s 
 
Odds ratio 
(95%CI) 
Adjusting 
for age, 
sex, 
method of 
admission 
reason for 
admission, 
type of 
trust, co-
morbiditie
s and 
deprivatio
n 
 
Odds ratio 
(95%CI) 
Age in years at start of 
admission 
1.065  
(1.064-
1.065) 
1.049 
(1.048-1.049) 
1.049  
(1.049-1.050) 
1.056  
(1.055-
1.058) 
1.046 
(1.045-
1.047) 
1.046 
(1.044-
1.047) 
Sex Male 1.225 
(1.211-
1.239) 
1.181 
(1.167-1.195) 
1.181  
(1.167-1.194) 
1.046 
(1.024-
1.069) 
0.995 
(0.973-
1.017) 
0.994 
(0.973-
1.017) 
Female - - - - - - 
Method of 
admission 
Elective * - - - - - - 
Emergency 7.122 
(6.941-
7.308) 
7.839 
(7.639-8.045) 
7.785  
(7.585-7.990) 
6.818 
(6.458-
7.198) 
6.988 
(6.619-
7.378) 
7.010 
(6.638-
7.402) 
Transfer 9.563 
(9.193-
9.948) 
9.751 
(9.369-
10.149) 
9.713  
(9.331-
10.111) 
10.417 
(9.380-
10.976) 
9.881 
(9.127-
10.696) 
9.980 
(9.125-
10.698) 
Healthcar
e 
Resource 
Group 
A – Nervous 
system 
3.045 
(2.967-
3.125) 
2.414 
(2.351-2.478) 
2.423  
(2.360-2.488) 
2.023 
(1.930-
2.120) 
1.813 
(1.728-
1.901) 
1.813 
(1.728-
1.902) 
B – Eyes and 
periorbita 
0.148 
(0.114-
0.191) 
0.203 
(0.157-0.263) 
0.202  
(0.156-0.262) 
0.120 
(0.072-
0.199) 
0.160 
(0.096-
0.267) 
0.161 
(0.097-
0.267) 
C – Mouth, 
head, neck & 
ears 
1.421 
(1.360-
1.484) 
1.392 
(1.332-1.455) 
1.396  
(1.335-1.459) 
1.244 
(1.139-
1.360) 
1.358 
(1.241-
1.485) 
1.352 
(1.236-
1.480) 
D – 
Respiratory 
system 
5.347 
(5.232-
5.465) 
3.360 
(3.286-3.435) 
3.342  
(3.268-3.417) 
3.506 
(3.381-
3.636) 
2.710 
(2.612-
2.812) 
2.714 
(2.615-
2.816) 
E – Cardiac 
surgery and 
primary 
cardiac 
conditions* 
- - - - - - 
F – Digestive 
system 
2.447 
(2.389-
2.507) 
1.824 
(1.780-1.869) 
1.828  
(1.784-1.874) 
1.771 
(1.699-
1.847) 
1.520 
(1.457-
1.586) 
1.520 
(1.457-
1.587) 
G – Hepato-
biliary and 
pancreatic 
system 
4.230 
(4.102-
4.362) 
3.048 
(2.952-3.146) 
3.048  
(2.953-3.147) 
3.237 
(3.069-
3.414) 
2.457 
(2.325-
2.596) 
2.463 
(2.331-
2.603) 
H – 
Musculoskelet
al system 
0.730 
(0.706-
0.755) 
0.736 
(0.711-0.761) 
0.739  
(0.715-0.765) 
0.693 
(0.652-
0.736) 
0.735 
(0.691-
0.781) 
0.735 
(0.691-
0.782) 
J – Skin, 
breast & 
burns 
1.281 
(1.227-
1.337) 
1.023 
(0.979-1.068) 
1.027  
(0.983-1.073) 
0.977 
(0.907-
1.053) 
0.948 
(0.879-
1.022) 
0.945 
(0.876-
1.020) 
K – Endocrine 
and metabolic 
system 
1.888 
(1.771-
2.013) 
1.250 
(1.171-1.335) 
1.256  
(1.177-1.341) 
0.690 
(0.641-
0.743) 
0.678 
(0.629-
0.730) 
0.676 
(0.628-
0.729) 
L – Urinary 
tract and 
male 
reproductive 
system 
1.576 
(1.529-
1.625) 
1.067 
(1.034-1.101) 
1.072  
(1.039-1.106) 
1.394 
(1.330-
1.462) 
1.144 
(1.090-
1.20) 
1.146 
(1.092-
1.203) 
M – Female 
reproductive 
system 
1.229 
(1.149-
1.313) 
1.065 
(0.996-1.139) 
1.007  
(1.000-1.144) 
1.749 
(1.487-
2.059) 
1.346 
(1.140-
1.590) 
1.357 
(1.149-
1.602) 
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P – Diseases of 
childhood and 
neonates 
1.256 
(1.141-
1.383) 
0.871 
(0.791-0.960) 
0.890  
(0.808-0.980) 
0.505 
(0.303-
0.843) 
0.562 
(0.337-
0.938) 
0.558 
(0.334-
0.932) 
Q – Vascular 
system 
8.359 
(8.101-
8.626) 
6.260 
(6.062-6.465) 
6.256  
(0.6057-
6.461) 
4.239 
(4.022-
4.468) 
4.008 
(3.800-
4.229) 
3.989 
(3.781-
4.209) 
R – Radiology 
and nuclear 
medicine 
3.244 
(2.332-
4.513) 
2.242 
(1.605-3.131) 
2.270  
(1.625-3.171) 
2.972 
(1.515-
5.829) 
2.356 
(1.197-
4.638) 
2.367 
(1.202-
4.659) 
S – 
Haematology, 
chemotherapy
, radiotherapy 
and specialist 
palliative care 
3.260 
(3.139-
3.386) 
1.599 
(1.538-1.662) 
1.614  
(1.552-1.677) 
1.737 
(1.602-
1.883) 
1.173 
(1.080-
1.273) 
1.169 
(1.076-
1.269) 
U – Undefined 
groups 
2.736 
(2.68-
2.848) 
2.698 
(2.589-2.811) 
2.709  
(2.600-2.824) 
2.311 
(2.128-
2.510) 
2.117 
(1.946-
2.302) 
2.110 
(1.940-
2.295) 
V – Multiple 
trauma, 
emergency 
medicine and 
rehabilitation 
2.620 
(2.455-
2.796) 
3.325 
(3.112-3.552) 
3.290  
(3.077-3.517) 
1.249 
(1.028-
1.517) 
1.495 
(1.227-
1.821) 
1.491 
(1.223-
1.818) 
W – 
Immunology, 
infectious 
diseases and 
other 
contacts with 
health service 
1.715 
(1.662-
1.769) 
1.469 
(1.424-1.517) 
1.473  
(1.427-1.521) 
1.651 
(1.567-
1.741) 
1.523 
(1.443-
1.607) 
1.526 
(1.447-
1.610) 
Type of 
trust 
Teaching trust 
* 
- - - - - - 
Large acute 
trust 
0.994  
(0.980-
1.009) 
1.091 
(1.075-1.108 
1.097  
(1.081-1.114) 
1.085  
(1.054-
1.117) 
1.151 1.148 
(1.114-
1.182) 
Medium acute 
trust 
0.967  
(0.951-
0.983) 
1.064 
(1.046-1.082) 
1.075  
(1.057-1.093) 
1.103  
(1.069-
1.139) 
1.183 1.178 
(1.140-
1.217) 
Small acute 
trust 
0.956 
(0.936-
0.976) 
1.083 
(1.060-1.106) 
1.104  
(1.080-1.128) 
1.132  
(1.088-
1.177) 
1.239 1.228 
(1.179-
1.279) 
Modified 
Charlson 
score 
0 # - - - - - 
1 # 2.765 
(2.716-2.815) 
2.736  
(2.687-2.785) 
# 2.142 
(2.070-
2.217) 
2.142 
(2.070-
2.218) 
2 # 4.776 
(4.684-4.868) 
4.751  
(4.661-4.844) 
# 3.425 
(3.305-
3.550) 
3.427 
(3.306-
3.551) 
3 # 6.871 
(6.709-7.037) 
6.798  
(6.637-6.962) 
# 4.597 
(4.414-
4.788) 
4.594 
(4.411-
4.786) 
4 # 10.429 
(10.104-
10.764) 
10.289  
(9.968-
10.621) 
# 6.462 
(6.141-
6.801) 
6.461 
(6.139-
6.801) 
5+ # 14.287 
(14.022-
14.557) 
14.328  
(14.061-
14.599) 
# 10.405 
(10.015-
10.811) 
10.383 
(9.993-
10.788) 
Deprivatio
n 
Most deprived  # # 0.966  
(0.951-0.983) 
# # 1.031 
(1.000-
1.063) 
2nd most 
deprived 
# # 0.921  
(0.906-0.937) 
# # 1.040 
(1.007-
1.073) 
3rd most 
deprived 
# # 0.882  
(0.866-0.897) 
# # 1.026 
(0.992-
1.062) 
2nd least 
deprived 
# # 0.857  
(0.841-0.873) 
# # 1.020 
(0.982-
1.059) 
Least 
deprived * 
- - - - - - 
Model statistics 
Chi-squared 260865.928 350657.189 349,437.24
5 
34564.840 51835.903 51,606.386 
Degrees of freedom 25 30 34 25 30 34 
-2 log likelihood 1,113,588.3
2 
1,023,797.06 1,017,863.
26 
285,951.20
3 
268,680.14
0 
267,668.27
4 
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P <0.005 <0.005 <0.005 <0.005 <0.005 <0.005 
* Indicates the reference group for the model, # indicates variable not included in model 
The impact of having a diagnosis of diabetes on the odds of dying in hospital 
varied by HRG chapter: admissions due to HRG J (skin, breast and burns), HRG L 
(urinary tract and male reproductive system) and HRG M (female reproductive 
system and assisted reproduction) had the highest additional risk of death 
associated with diabetes.  Admissions among patients with recorded diabetes 
admitted for HRG Q (vascular system) had a lower risk of dying than those 
without diabetes (361 (15.7%) fewer deaths over the two year period).  The 
greatest numbers of additional deaths were in HRG chapters E (cardiac surgery 
and primary cardiac conditions) and L (urinary tract and male reproductive 
system) (see Table 3.3). 
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Table 3.3: Additional deaths by HRG chapter after standardisation for age, 
sex, method of admission, modified Charlson score and type of trust for 
patients with a diagnosis of diabetes 
 Odds ratio (95% CI) 
Total 
deaths 
Additional 
deaths 
n (%) 
A - The nervous system 0.978 (0.938-1.02) 3,008 -63 (-2.11%) 
B - Eyes and periobita 1.104 (0.613-1.989) 15 2 (10.42%) 
C - Mouth, head, neck & ears 1.221 (1.108-1.345) 574 126 (21.94%) 
D - Respiratory system 1.002 (0.978-1.027) 9,355 19 (0.21%) 
E - Cardiac surgery and primary cardiac 
conditions 
1.182 (1.141-1.225) 4,825 866 (17.95%) 
F - Digestive system 1.029 (0.994-1.065) 4,564 130 (2.85%) 
G - Hepato-biliary and pancreatic system 1.043 (0.988-1.1) 2,134 89 (4.16%) 
H - Musculoskeletal system 1.221 (1.148-1.3) 1,385 305 (22.01%) 
J - Skin, breast and burns 1.3 (1.193-1.415) 844 251 (29.72%) 
K - Endocrine and metabolic system 0.674 (0.613-0.742) 869 -280 (-32.23%) 
L - Urinary tract and male reproductive 
system 
1.288 (1.23-1.349) 2,895 822 (28.38%) 
M - Female reproductive system 1.262 (1.042-1.528) 158 41 (26.09%) 
P - Diseases of childhood and neonates 1.337 (0.795-2.248) 15 5 (33.67%) 
Q - Vascular system 0.836 (0.794-0.88) 2,303 -361 (-15.68%) 
R - Radiology and nuclear medicine 1.386 (0.643-2.986) 9 3 (37.99%) 
S - Haematology, chemotherapy, 
radiotherapy and specialist palliative 
care 
0.917 (0.843-0.998) 720 -58 (-8.08%) 
U - Undefined groups 0.985 (0.902-1.075) 703 -11 (-1.53%) 
V - Multiple trauma, emergency medicine 
and rehabilitation 
0.853 (0.691-1.053) 108 -16 (-14.43%) 
W - Immunology, infectious diseases and 
other contacts with health services 
1.226 (1.163-1.293) 2,120 473 (22.33%) 
    
All HRG chapters 1.065 (1.052-1.079) 36,622 2316 (6.32%) 
Note: Sum of excess deaths split by HRG do not sum up to total excess deaths due to rounding. 
 
There were significant differences in the odds ratio of death associated with a 
diagnosis of diabetes by the type of provider trust (1.029 95% CI 1.001-1.058 for 
acute teaching trusts, 1.049 (95% CI 1.029-1.069) for large acute trusts, 1.097 
(95% CI 1.071-1.124) for medium acute trusts and 1.128 (95% CI 1.087-1.171) for 
small acute trusts).  When trust level mortality among admission in patients with 
recorded diabetes was standardised to mortality among admissions for patients 
in the same trust without diabetes (taking account of age, sex, co-morbidities, 
deprivation, method of admission and HRG chapter) there were six (4.1%) trusts 
above and nine (6.2%) trusts below the 95% confidence interval.  Using this 
measure mortality in admissions for patients with recorded diabetes was 
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significantly lower than inpatients without recorded diabetes in four (2.7%) 
trusts (see Figure 3.1).  
 
Figure 3.1: Trust level standardised mortality ratio of admissions among patients 
with diabetes compared to patients without diabetes in the same trust 
 
 
 
There was greater variation in the trust level mortality ratios for admissions in 
patients with recorded diabetes standardised to all admissions among patients 
with recorded diabetes across the 146 trusts in the analysis.  16 (11.0%) trusts 
were above and 24 (16.4%) trusts were below the 95% confidence interval (see 
Figure 3.2).  There was a positive correlation between this standardised 
diabetes mortality ratio and the comparable ratio for admissions without 
recorded diabetes included in this analysis (r=0.615, p<0.005); there were 
similar correlations with both of the published standardised hospital mortality 
ratios SHMI (r=0.677, p<0.005) and HMSR (r=0.533, p<0.005).  These measures of 
general hospital mortality explained 37.4%, 39.6% and 32.9% of the variation 
respectively (F=87.729, p<0.005, F=96.146, p<0.005 and F=71.961, p<0.005).    
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Figure 3.2: Relative risk of death for admissions among patients with diabetes in 
each trust compared to all admissions among patients with diabetes in the 
analysis 
 
 
 
Discussion 
 
After adjustment for case mix, admissions among patients with recorded 
diabetes were 6.3% more likely to die during a hospital stay than those without 
diabetes recorded. There was an adverse impact of diagnosed diabetes 
unexplained by other presently recognised case-mix factors.  This equates to 
approximately 2,300 additional deaths per year in England.  These deaths 
represent one in sixteen of the deaths in hospital among patients with diabetes, 
one in sixty (1.4%) of all hospital deaths and approximately 10% of the estimated 
22,000 excess deaths among people with diabetes each year in England [55]. 
 
The additional risk of death found in admissions among patients with diabetes 
(5.6%) is lower than the additional risk of all-cause mortality for people with 
diabetes (40%) found by a study of all deaths among the 1.9 million people 
included in the National Diabetes Audit 2009/10 [55].  This is to be expected as 
the National Diabetes Audit analysis compared mortality among those with 
diabetes to the general population whereas the comparable population in this 
study is at a much greater risk of dying irrespective of their diabetes status.  In 
64 
 
addition, this analysis includes a more comprehensive case-mix adjustment, in 
particular assessment of co-morbidities that have a significant impact on the risk 
of death.  A ten year study of hospital mortality in a tertiary setting in Greece 
found that patients with Type 2 diabetes had a mortality rate 28% higher than 
patients without diabetes [71]. The unadjusted additional risk of death among 
inpatients with diabetes in this English analysis was similar to that found in a US 
study of mortality among inpatients with diagnosed diabetes, hyperglycaemia 
without a diagnosis of diabetes or normoglycaemic patients [72].  However, 
adjustments for case mix were not included in these studies so it is difficult to 
assess the comparative independent impact of a diabetes diagnosis on hospital 
mortality.  This analysis found that adjustments for case mix substantially 
reduced the crude odds of dying associated with a diagnosis of diabetes.   
 
This analysis did not find coherent deprivation gradients in the risk of death for 
admissions among patients either with or without diabetes. The National 
Diabetes Audit 2010/11 found clear deprivation gradients in all-cause mortality; 
people with diabetes living in the most deprived fifth of neighbourhoods had 37% 
greater odds of dying compared to those in the least deprived quintile [55]. 
Thus, although there is a deprivation gradient in the prevalence of diabetes [14], 
these inequalities are not exacerbated by hospital care and a diagnosis of 
diabetes has a stronger influence on hospital mortality than the patient’s social 
background. Amongst admissions in patients with recorded diabetes the elderly, 
males and those admitted as an emergency had the smallest additional risks of 
dying in hospital. These are categories which are generally associated with the 
highest risks of in-hospital death. For admissions with recorded diabetes, 
however, the greatest additional risks were in admissions that would generally 
have low risks of death in hospital; these findings suggest an influence of 
diabetes on hospital mortality that partially overrides the usual inpatient 
mortality risk factors.   
 
After adjustment for case-mix the additional risk of dying associated with a 
diagnosis of diabetes is significantly higher in medium and small provider trusts.  
This suggests that factors relating to the organisation and delivery of care may 
influence the risk of dying in hospital.  When all trusts are analysed individually 
the extent of variation in the additional risk of death associated with a diagnosis 
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of diabetes there are approximately twice the number of trusts outside the 
confidence intervals than would be expected.  The trust level variation is even 
greater when mortality among admissions in patients with diabetes are 
compared to similar admissions across England is considered.  The significant 
correlation between general hospital mortality measures and mortality in 
admissions among patients with diabetes standardised across England means that 
approximately a third of the trust level variation is associated with differences 
in all-patient mortality between provider trusts.  The fact that the measure of 
mortality among inpatients without diabetes and the general measures of 
inpatient mortality show a similar relationship with mortality among inpatient 
with diabetes supports the reliability of this finding. However, approximately 
half of the local level variation remains unexplained suggesting local differences 
in diabetes care may be responsible. 
 
The additional risk of death varied according to the reason for admission.  
Admissions for cardiac disease and surgery or urinary tract disease and surgery 
showed the highest number of additional deaths. There is a large literature on 
the relationship between blood glucose levels and outcome from acute cardiac 
events [58–60].  However, the National Diabetes Inpatient Audit 2011 showed 
that, on average, inpatients with diabetes had target blood glucose control on 
only four out of seven days [61].  The concentration of additional deaths among 
inpatients admitted for urinary tract disease is likely to reflect the increased 
prevalence of chronic kidney disease among people with diabetes and their 
higher mortality on dialysis [73]. 
 
By analysing over one million hospital admissions where diabetes was recorded 
this study provides a comprehensive assessment of in-hospital mortality among 
patients with diabetes. The reliability of the findings is enhanced by the use of 
death as the outcome measure because it is not associated with recording 
biases.  However, the measurement of mortality in this study is limited to deaths 
in hospital and does not include deaths that may occur shortly after discharge.  
Unlike some measures of hospital mortality, deaths associated with terminal 
illness have not been excluded so it is not legitimate to compare these findings 
directly with other commonly published rates.  It is also possible that local 
provision and organisation of palliative care, in particular care for people with 
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multi-morbidities will explain some of local variation in the additional mortality 
found among hospital admissions in patients with diabetes.  Nonetheless, 
because the same analysis was applied to admissions for patients with and 
without recorded diabetes the deductions about the impact of diabetes are 
reliable.   
 
This analysis relies on discharge coding to identify patients that have diabetes.  
There are clear incentives for hospitals to ensure the accurate coding of long 
term conditions such as diabetes in the Payments for Results system.  However, 
scepticism about the reliability Hospital Episode Statistics in identifying patients 
with diabetes persists.  A recent study of hospital admissions among a cohort of 
1.6 million people with diagnosed diabetes found that there was under recording 
of diabetes as a discharge diagnosis.  However, for patients in whom diagnosed 
diabetes was not included in the discharge coding the length of stay, day case 
listing and emergency re-admissions were similar to those for patients without 
diabetes whereas they were markedly different in patients with recorded 
diabetes [52]. This suggests that patients with diabetes not recorded in 
discharge coding have hospital experiences similar to their peers without 
diabetes.  It is therefore plausible that this study underestimates the number of 
admissions and over estimates the additional risk of death among the totality of 
admissions among patients with diabetes. Coding practices mean that it is not 
possible reliably to identify the type of diabetes and treatment regimen, 
duration of diabetes, bio-chemical markers and specific cause of death are is not 
recorded in HES.  As a result, the scope to assess inpatient mortality by sub-
group and report cause specific mortality is limited.   
 
This study has assessed the current extent and characteristics of hospital 
mortality in admissions among patients with recorded diabetes across the full 
spectrum of secondary and tertiary care in England. It suggests a diabetes 
specific effect.  Further research should consider the cause of death among 
inpatients with diabetes and, in light of the findings that the additional risk of 
dying is significantly higher in smaller non-specialist trusts, explore the 
associations between healthcare organisation and delivery and mortality.   
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Update since publication 
A recent literature review has not identified any similar studies that consider 
mortality among inpatients with diabetes across the full spectrum of healthcare.   
The Summary Hospital-level Mortality Indicator (https://digital.nhs.uk/data-and-
information/publications/ci-hub/summary-hospital-level-mortality-indicator-
shmi) continues to be published by NHS Digital.  The figures now report on a 
rolling 12-month period with monthly updates.  This provides a timely 
assessment of mortality for people admitted to hospital for diabetic specific 
causes but the information and understanding of the full pattern of hospital 
mortality for people with diabetes remains limited. 
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Chapter 4: The development of a national audit of foot care for 
people with diabetes: Pilot work for the National Diabetes Foot 
Audit 
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Introduction 
 
Increasing awareness of the size of the clinical and economic burden posed by 
disease of the foot in diabetes has meant that attempts to improve outcome 
have become a clinical priority. However, improvement in clinical care is 
dependent on knowledge of the effectiveness of current practices. Such insight 
will lead to recognition of differences in clinical outcome, where they exist, and 
this in turn will help identify key aspects of best practice, both clinically and 
administratively. These developments are, however, dependent on the existence 
of reliable measures of the structures, processes and outcomes of routine care in 
different clinical services. Without such measures, clinicians are to a large 
extent unaware of both the effectiveness of their own practice and of the 
changes that could be made to improve it.  
 
Guidance exists on the identification, prevention of risk and management of 
diabetic foot disease in England [74–76] and elsewhere [77,78] but there are no 
data to demonstrate either how widely this guidance is adopted or for assessing 
its impact. Hitherto, the measure which has been most widely used is the 
incidence of amputation, and wide variation has been shown in the amputation 
rates across England [79] and in other countries [80] but the incidence of 
amputation is a measure which is acknowledged to require careful 
interpretation. Variation has also been reported in the incidence of hospital 
admissions for diabetic foot disease in England [81] and one formal prospective 
study has reported quite large differences in practice and clinical outcome 
between 14 specialist centres throughout Europe [82]. These variations in 
outcome imply geographical inconsistency in the quality of care provided and 
may reflect differences in either the approach to ulcer management or service 
organisation, both within countries and between them. 
 
This study formed part of an initiative to develop and test a dataset and data 
collection methodology with the aim of creating an audit tool that could be used 
in any setting to assess diabetic foot service provision against current guidelines. 
The focus of this report is on the development of a measurement methodology 
relating to the management of active ulceration.  
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Methods 
 
A national working group was established as part of the National Diabetes Audit 
programme in England and Wales [83] to consider measures for the assessment 
of different aspects of the pathway of care of disease of the foot in diabetes. 
These included details of the structure, process and outcomes of care. In order 
to audit the process of management of active ulceration, an email invitation was 
sent in June 2011 to representatives of specialist foot care services known to 
NHS England, inviting them to complete questionnaires on all people presenting 
will active ulceration of the foot over a three month period. If an individual had 
more than one lesion, one – assessed to be the largest or most clinically 
significant – was selected as the index ulcer.  
 
A trial dataset was created following discussion within the working group, and 
comprised questions on the following topics: 
 
(a) Details of people with foot ulcers:  
demographics, postcode to allow assessment of social deprivation, 
diabetes type and duration, previous use of podiatry and receipt of foot 
protection advice, and previously determined foot risk score determined 
by their usual carer 
 
(b) Details of the index ulcer:  
classification and score derived using the SINBAD system which is a six 
point score based on the site, depth and area of the ulcer and the 
presence of infection, ischemia and neuropathy (see Table 4.1 for details) 
[84], time and date of first presentation with the index ulcer to any 
healthcare professional, time and date of assessment by the specialist 
multi-disciplinary foot team (MDT) and whether the ulcer developed 
during a hospital admission 
 
(c) Outcomes of the index ulcer at six and twelve months after 
presentation to the specialist MDT:  date of ulcer healing if within 365 
days, time to healing, amputation, hospital admission, death 
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(d) Well-being and function: 
People included in the study were asked at presentation and at latest 
review to complete an EQ5D–3L [85] questionnaire, including assessment 
of current well-being and function.  
 
After all data had been submitted, semi-structured telephone interviews were 
conducted with a representative of each unit and an attempt was made to 
identify common themes. The result of this feedback was used in conjunction 
with an assessment of data quality to devise a refined audit dataset and data 
collection methodology.  
 
Statistical analysis 
Statistical significance was calculated using chi-squared tests for categorical 
variables, t-tests for the difference in means between two groups and one-way 
analysis of variance for differences in continuous variables between categories. 
A step-wise binary regression model was created to assess the relative 
independent impact of demographic and ulcer characteristics on the chance of 
the ulcer healing within 12 and 24 weeks.  Although the healing data was 
collected as continuous time to event data it was converted into dichotomous 
variables for analysis and logistic regression was undertaken to test the use of 
the methods that would be applied to the revised data to be collected in the 
national audit programme.  The coefficients for healing at 24 weeks were used 
to identify the personalised probability of ulcer healing of each person in the 
study. For each participating centre that reported more than one healed ulcer 
the sum of these probabilities was compared with the actual number of peoples 
with healed ulcers to provide a standardised case-mix adjusted healing ratio 
(SHR). Byar’s method was used to calculate 95% and 99% confidence intervals for 
each SHR [66]. Data analysis was performed in Excel 2007 and IBM SPSS 21.   
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Results 
 
Clinical characteristics and outcomes 
Demographic and ulcer characteristics at presentation 
Twenty three units provided data on the process of management of 652 peoples 
newly presenting with a diabetic foot ulcer.  The mean age was 65.2 (SD 14.3) 
years and 451 (69.2%) were male (Table 4.1). 89 (13.7%) had Type 1 diabetes, 
550 (84.4%) had Type 2 diabetes and 13 (2.0%) had genetic, other or unknown 
type of diabetes.  The majority (581 or 89.1%) were from White ethnic groups.  It 
was possible to derive a deprivation score from postcodes for 601 (92.2%) 
people; 185 (30.8% of 601) lived in the most deprived quintile of areas in England 
while 86 (14.3%) lived in the least deprived quintile.   
 
Table 4.1: Ulcer SINBAD score at presentation to the multi-disciplinary foot 
team 
 N (%) 
Site - Ulcer on midfoot or hind foot (rather than forefoot) 158 (24.2%) 
Ischaemia - Clinical evidence of reduced blood flow 247 (37.9%) 
Neuropathy – Protective sensation lost  548 (84.0%) 
Bacterial infection – Present 322 (49.4%) 
Area – Ulcer equal to or greater than 1cm2 318 (48.8%) 
Depth – Involving the muscle, tendon or deeper 168 (25.8%) 
  
SINBAD score 0 23 (3.5%) 
SINBAD score 1 111 (17.0%) 
SINBAD score 2 172 (26.4%) 
SINBAD score 3 162 (24.8%) 
SINBAD score 4 110 (16.9%) 
SINBAD score 5 64 (9.8%) 
SINBAD score 6 10 (1.5%) 
Each ulcer is allocated one point for each aspect of the score  
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617 (94.6%) of the population had a valid pre-ulcer risk score recorded of whom 
453 (73.4%) had been assessed to be high risk, 134 (21.7%) increased risk and 30 
(4.9%) low risk. 605 (92.8%) had previously been seen for foot protection advice 
by one or more healthcare professionals: podiatrist (71.8%), general practitioner 
(27.1%), diabetologist (24.5%) practice nurse (17.2%), solely or in combination. 
People previously identified as being at high risk of future ulceration were more 
likely to have received foot protection advice or care (97.6% high risk, 91.8% 
increased risk, 86.7% of peoples at low risk (χ2 15.058, p=0.001).   
 
Valid data for time of first presentation to a healthcare professional and of 
assessment by the multi-disciplinary foot team was available for only 460 (70.6%) 
of cases. Therefore it was not possible to assess the proportion of people that 
accessed the MDT within 24 hours of first presentation, as recommended by UK 
guidance [76].  For people with both a valid date of first presentation to any 
healthcare professional and a date of first assessment by the MDT, 280 (60.9%) 
reached the MDT in <2 days. 346 (53.1%) people had an index ulcer with a 
SINBAD score of >3, which has previously been associated with worse prognosis. 
Twenty six (4.0%) people developed their ulcers whilst a hospital inpatient. 
 
Outcomes 
Valid outcome data were recorded for 541 (83.0%) people.  92 (21.1%) people 
were admitted to hospital for ulcer management. 267 (49.4% of 541) index ulcers 
healed within 12 weeks increasing to 351 (64.9%) at 24 weeks. The median time 
to healing was 63 days (range 5–359).  There was no difference in the mean age 
of people whose ulcers healed when compared with those that didn’t (65.8 
versus 64.5 years, t=1.075, p=0.282 at 12 weeks and 66.6 versus 64.4 years, 
t=1.804, p=0.076 at 24 weeks). The proportion of people with a SINBAD score of 
3 or greater seen by the MDT within two days was similar to those who took 
longer (53.2% vs 53.9% chi-squared=0.028, p=0.866). Longer healing times were 
associated with higher SINBAD scores at presentation (Table 4.2).  
  
74 
 
Table 4.2: Time to healing by SINBAD score 
SINBAD 
score 
Healed within 
one year 
N (%) 
Healed within 12 
weeks 
 N (%) 
Healed within 24 
weeks  
N (%) 
Time to 
healing 
median (range) 
0 17 (89.5) 11 (57.9) 16 (84.2) 40 (13-196) 
1 89 (89.0) 70 (70.0) 86 (86.0) 47 (6-343) 
2 120 (81.1) 83 (56.1) 103 (69.6) 57 (7-359) 
3 92 (69.7) 63 (47.7) 80 (60.6) 72 (14-333) 
4 54 (64.3) 28 (33.3) 48 (57.1) 87 (5-275) 
5 21 (41.2) 10 (19.6) 16 (31.4) 108 (27-309) 
6 4 (57.1) 2 (28.6) 2 (28.6) 160 (34-267) 
 Chi-square = 
69.219 
p<0.005 
Chi-square = 
48.315 
p<0.005 
Chi-square = 
56.580 
p<0.005 
 
 
Univariate analysis showed that there were no significant differences in the 
incidence of ulcer healing by personal characteristics (sex, ethnic group, 
deprivation, previously defined foot risk). The incidence of healing was no 
greater if the time from first assessment by a healthcare professional to 
assessment by the MDT was >2 days.  Healing at both 12 and 24 weeks was less 
likely if the ulcer site was on the mid- or hind-foot, had a larger area (>1 cm2) or 
greater depth (involving the muscle, tendon or bone) or if there was clinical 
evidence of peripheral arterial disease (PAD).  Bacterial infection was associated 
with lower healing rates at 12 weeks but the difference was not statistically 
significant at 24 weeks whilst the loss of protective sensation was not associated 
with differences in healing (see Table 4.3).  
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Table 4.3: Univariate assessment of ulcer healing by demographic and ulcer 
characteristics 
 12 weeks 24 weeks 
N (%) p N (%) p 
Sex Males 179 (48.4) 
0.505 
241 (65.1) 
0.855 
Females 88 (51.5) 110 (64.3) 
Type of 
diabetes 
Type 1 34 (52.3) 
0.877 
39 (60.0) 
0.579 Type 2 229 (48.9) 306 (65.4) 
Other 4 (50.0) 6 (75.0) 
Ethnic 
group 
White 231 (48.2) 
0.500 
307 (64.6) 
0.565 
Asian 20 (60.6) 25 (75.8) 
Black 5 (50.0) 6 (60.0) 
Other 6 (60.0) 6 (60.0) 
Deprivatio
n 
Most deprived  84 (51.2) 
0.924 
110 (67.1) 
0.917 
2nd most deprived 44 (45.8) 59 (61.5) 
3rd most deprived 52 (51.5) 66 (65.3) 
2nd least deprived 40 (50.0) 52 (65.0) 
Least deprived 28 (48.3) 39 (67.2) 
Foot risk 
prior to 
ulcer 
High 184 (49.1) 
0.697 
232 (61.9) 
0.026 Increased 60 (53.1) 83 (73.5) 
Low 13 (54.2) 19 (79.2) 
Time to 
see MDFT 
Within 2 days 143 (43.8) 
0.012 
176 (67.4) 
0.160 
Longer than 2 days 114 (54.8) 160 (61.5) 
SINBAD 
score 
elements 
Forefoot 221 (53.0) 
0.002 
289 (69.3) 
<0.005 
Mid- or hind-foot 46 (37.1) 62 (50.0) 
At least one pulse palpable 193 (55.3) 
<0.005 
254 (72.8) 
<0.005 Clinical evidence of reduced blood 
flow 
74 (38.5) 97 (50.5) 
Protective sensation intact 35 (41.2) 
0.101 
54 (63.5) 
0.776 
Protective sensation lost 232 (50.9) 297 (65.1) 
No bacterial infection 162 (58.5) 
<0.005 
195 (70.4) 
0.006 
Bacterial infection present 105 (39.8) 156 (59.1) 
Ulcer less than 1cm2 162 (57.8) 
<0.005 
208 (73.2) 
<0.005 
Ulcer greater or equal to 1cm2 105 (40.9) 143 (55.6) 
Ulcer involving skin and subcutaneous 
tissue  
230 (56.2) 
<0.005 
290 (70.9) 
<0.005 
Ulcer involving the muscle tendon or 
deeper 
37 (28.0) 61 (46.2) 
 
  
76 
 
The multivariate regression model showed that mid- or hind-foot location, 
greater depth or accompanying clinical evidence of PAD were associated with 
reduced likelihood of healing (Table 4.4). Age, sex, type of diabetes, 
deprivation, risk assessment prior to ulceration and time to MDT assessment 
were not independently associated with healing.  
 
Table 4.4: Binary logistic regression models 
 Healed at 12 weeks 
Odds ratio (95% CI) 
Healed at 24 
weeks Odds ratio 
(95% CI) 
SINBAD 
score 
elements 
Mid- or hind-foot 
(rather than forefoot) 
0.625 (0.394-0.993) 
0.527 (0.329-
0.844) 
Clinical evidence of reduced blood flow 
(rather than at least one palpable 
pulse) 
0.471 (0.312-0.709) 
0.356 (0.233-
0.544) 
Ulcer involving the muscle, tendon or 
deeper (rather than just skin and 
subcutaneous tissue) 
0.313 (0.195-0.503) 
0.334 (0.210-
0.531) 
Model statistics (-2 log likelihood, p) 579.868, <0.005 524.174, <0.005 
 
The regression model finding that ulcer site, depth and the presence or not of 
clinical evidence of PAD were independent determinants of healing enabled 
standardised healing ratios (SHRs) to be calculated for 21 of the 23 participating 
clinics. Three (14.9%) units had a SHR above the 95% confidence interval and five 
(23.8%) had a SHR below the 95% confidence interval (see Figure 4.1). 
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Figure 4.1: Funnel plot of standardised healing ratios showing the scatter 
observed between participating centres 
 
 
 
EQ5D-3L 
A valid self-assessment of well-being and function on the EQ5D-3L visual 
analogue scale was reported for 618 (94.8%) people at presentation but for only 
378 (58.0%) at the time of outcome recording; complete data were available for 
376 (57.7%). At presentation the mean self-reported assessment of health was 
58.3 (SD 21.8).  At outcome recording the mean score was 65.0 (SD 22.9). 
Assessments of well-being improved by a mean 5.0 points (SD19.7) if the ulcer 
had healed and by a mean 1.0 point (SD 31.6) if it had been resolved by 
amputation. People with an unhealed ulcer at latest follow-up reported a mean 
7.05 (SD16.8) point deterioration in well-being (F=6.734, p<0.005).   
 
Feedback from participating units 
Common themes emerging from interviews with participating centres were 
difficulty (i) with precise recording of the date and time of first presentation, 
(ii) in defining the identity of professionals who had undertaken earlier foot 
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screening (iv) in determining the allocated pre-ulcer risk score, and (iv) in 
ascertaining who had cared for the ulcer prior to first specialist assessment. All 
but one of the participants found the SINBAD grading easy to use and useful in 
clinical documentation. There were mixed views on the EQ-5D questionnaire. 
Some found it very easy to administer but others found it difficult to explain that 
it was a ‘holistic’ view of current health status and not just concerned with the 
presenting problem. It was also difficult to use if English was not the person with 
diabetes’s first language. Whilst the audit record took less than ten minutes to 
complete, most sites reported that this presented too much of a burden in busy 
clinics, with the result that the ulcers reported did not always constitute a 
consecutive series and therefore potentially introduced a bias in the data 
collected.  All participants emphasised the need to minimise the burden of data 
collection.  
 
Discussion 
 
The data collected in this study not only lay a foundation for recommending an 
operational audit dataset but also provide some insight into the current 
outcomes of the management of diabetic foot ulcers by specialist teams in 
England. About half (49.4%) of ulcers reported had healed within 12 weeks. The 
characteristics of the people included in this analysis are similar to those at the 
English centre that originally validated the SINBAD score, though the median 
healing times at 12 and 24 weeks reported here are slightly lower [84]. This 
difference may reflect clinical advances over the intervening ten years, but may 
also reflect a change towards more prompt and less selective referral to 
specialist services in UK, as recommended in current guidance.  The ulcer 
healing rate is also broadly comparable with other UK and European studies: foot 
ulcers healing without amputation at 12 months have previously been reported 
to be 65% percent by 12 months in 194 peoples managed in one of two centres 
[86], 65.7% of 449 peoples in a single centre study from UK [87] and 64% in the 
Eurodiale study [82].  It should be noted that the data used in the present study 
were provided by volunteer units and that all published data also derive from 
those with a specialist interest. In the absence of information that is routinely 
collected in a representative cross section of services, it is not possible to 
determine the extent to which these findings reflect outcome in general.  
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People likely to have the poorest outcomes (eg those presenting as an 
emergency and requiring immediate surgical intervention, vulnerable people 
who are not able to attend specialist centres) are often not managed by 
specialist foot care teams. 
 
This study has found that some presenting ulcer characteristics (area, clinical 
evidence of arterial disease and site) are clearly associated with healing but 
personal and demographic characteristics are not. Although it is well known that 
diabetic foot disease and amputation, in particular, are more prevalent amongst 
White ethnic groups as well as among males living in deprived areas [55,88,89] 
we found no link in this study between outcome and either ethnic group or social 
deprivation. The lack of relationship between healing and deprivation was also 
reported earlier in a single centre cohort in UK of similar size [90]. This 
discordance in relationships may be because the greatest impact of race and 
deprivation (in a country like England, with universal access to health care 
services) is on ulcer onset, whereas the state of the ulcer at presentation is the 
more important determinant of healing. It is similarly not surprising that 
neuropathy was not associated with healing rates because it, too, is likely to be 
a risk factor primarily for ulcer onset.  
 
The results of this study further validated the SINBAD score at ulcer presentation 
as a reliable assessment of ulcer severity in that it was linked to measures of 
outcome; ulcers with a SINBAD score of three or greater are both less likely to 
heal, and to take longer when they do. It is probable that elements of the 
SINBAD score override the time to first multi-disciplinary foot team visit as an 
outcome predictor. This, together with difficulties in acquiring accurate data on 
ulcer duration at the time of referral, would explain the lack of an association 
between ulcer duration and clinical outcome when compared with previous 
observations [90,91] – although it should be noted that these earlier observations 
were based solely on those with neuropathic ulcers and that there are no 
equivalent data for unselected populations. Nevertheless, it is very likely that 
delayed referral is a direct cause of worse ulcer state  at first specialist 
assessment and  the implication is that improved outcome reflects not only a 
reduction in the time to assessment by a MDT but also earlier implementation of 
customised management of particular ulcer types. This would resonate with 
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clinical experience. The use of a case-mix adjusted healing ratio (SHR) was 
explored in this pilot and the findings suggest that this approach could be used 
by units to benchmark their performance against peer services –whether in UK or 
other countries. 
 
Assessment of quality of life is multi-dimensional and dependent on many factors 
which may be outside the scope of the healthcare setting being considered.  It is 
particularly complex in a patient population, such as the one in this analysis, 
with a high prevalence of multiple and often severe co-morbidities [92,93].  This 
is reflected in the low proportion of people with valid data to assess change in 
quality of life.  However, the improvement in quality of life reported by people 
whose ulcer healed and the deterioration in quality of life reported by people 
whose ulcer remained unhealed serves to highlight the health burden created by 
the delayed healing that typifies the condition and confirms earlier reports from 
large multicentre studies [94,95].  The small improvement in reported well-
being by people who underwent an amputation is similar to other reports [96] 
and supports the view that, where appropriate, amputations can represent 
positive treatment for people with diabetic foot disease.   
 
The primary purpose of this study, however, was not to study outcome in a 
cohort of people presenting with foot diseases but to pilot a process for 
measuring the management of diabetic foot ulcers by specialist teams. It 
successfully tested a provisional methodology in 23 units across England, even 
though the users found some aspects of recording data onerous – which suggests 
that the questions used would be difficult to implement in routine practice.  The 
lack of follow up data on a significant minority of people can be in part 
attributed to the difficulty in identifying outcomes after people have been 
discharged from the specialist unit.  In England and Wales, however, it would be 
feasible to reduce the imposed recording burden by using the unique national 
NHS number to link to data stored by the National Diabetes Audit. These data 
include demographics (age, sex, ethnic group, deprivation score), diabetes 
management characteristics (type and duration of diabetes, HbA1c, blood 
pressure, cholesterol, estimated glomerular filtration rate; foot examination), 
hospital admissions for the management of diabetic foot disease, amputations 
and mortality thereby ensuring that some outcome data for all people included 
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in the audit irrespective whether locally collected outcome data were provided. 
This would markedly reduce the burden of local data collection from twenty five 
fields to ten and yet permit reliable measurement of case-mix adjusted 
performance against current guidelines, as well as linkage between aspects of 
performance and measures of clinical outcome. The inclusion of foot disease in 
the national programme of audits should make it easier for teams to access local 
audit support which will be vital to ensuring robust local data collection.  
Nevertheless, it is clear that the number of items that need to be collected by 
clinicians working in busy routine practice must be further reduced if the data 
recorded are to be both complete and reliable – especially if the plan is that 
audit data are collected for all new referrals, without selection. The reduced 
data-set currently being considered is shown in Table 4.5. 
 
Table 4.5: Recommended measurement dataset for local recording in a 
specialist foot care clinic 
 
Identifiable information  
to allow linkage to core National Diabetes 
Audit, data on hospital admissions and 
deaths 
NHS number 
Referral for specialist assessment 
Time from first presentation to a health 
care professional to time of first 
assessment by a member of the MDT        
Less than 2 days 
2 days or more but less than 2 weeks 
2 weeks of more  but less than 2 months 
2 months or more 
Ulcer type and severity at presentation SINBAD classification and score at first 
expert assessment  
Whether there is evidence of charcot 
neuroarthropathy 
Outcomes at 12 and 24 weeks after first 
assessment by the multi-disciplinary 
foot team 
Whether the person is alive an ulcer free 
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Participating centres 
Aintree Hospital, Arrowe Park and Clatterbridge Hospitals, Bradford Hospitals 
Rapid Access Foot Ulcer Clinic, Ipswich Hospital, King’s Mill Hospital, Newcastle 
Diabetes Centre, North Middlesex University Hospital, Northampton General 
Hospital and Battle House, Northern General and Royal Hallamshire Hospitals, 
Poole Hospital, Royal Devon and Exeter Hospital, Royal Free Hospital, Royal 
Liverpool and Broadgreen University Hospitals, Royal United Hospital, Salford 
Royal Hospital, Southport and Ormskirk Hospital, St Helens and Knowsley 
Teaching Hospitals NHS Trust, Stoke Mandeville and Wycombe General Hospitals, 
Thomas Addison Unit, St Georges Hospital, University Hospitals of Leicester NHS 
Trust, Warrington and Halton Hospitals, Watford General, St Albans City and 
Hemel Hempstead General Hospitals, Whittington Hospital 
 
Update since publication 
Since the publication of this work, the methodology and findings have been 
handed over to NHS Digital to inform the implantation of the National Diabetes 
Footcare Audit (NDFA).  NDFA started collecting data in 2014 as an ongoing, 
rolling data collection of people presenting to multi-disciplinary foot teams with 
an incident diabetic foot ulcer [97].  It aims to collect data on the 
characteristics, clinical care and outcomes of all people presenting to multi-
disciplinary foot care teas across England and Wales.   
 
The latest report covers the period 1st April 2015 to 31st March 2018 and includes 
data on 33,155 new foot ulcer episodes in 27,700 people [98].  The findings of 
this larger cohort spanning a longer time period are similar to those found in the 
pilot study and presented above. Just under half (48.7%) of people were alive 
and ulcer free 12 weeks after initial presentation to the multi-disciplinary team.  
This compares to 49.4% in the pilot data collection.  The organisational 
placement of the NDFA as managed by NHS Digital and part of the group of 
audits included in the National Diabetes Audit facilitates easy linkage to the core 
National Diabetes Audit data to include data on risk factors and intermediate 
diabetes outcomes.  Regression models seeking to explain the chance of being 
alive and ulcer free 12 weeks after presentation indicated that ulcer 
characteristics (ischemia, area and depth) are the strongest predictors of this 
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outcome.  Another notable finding was that duration of diagnosed diabetes is 
statistically significantly associated with being alive and ulcer free at 12 weeks 
after initial presentation but no such association exists with age at presentation 
with foot ulcer.     
 
One of the key aims of the pilot and subsequently the NDFA was to identify a 
methodology for appropriately identifying variation in outcomes amongst those 
presenting with diabetic foot ulcers.  The high level of co-morbidity amongst this 
group and the chronic nature of ulcers make crude outcomes rates a blunt 
measure.  The approach taken in NDFA follows the methodology of the 
standardised healing ratio detailed above but expands the variables included in 
the case mix adjustment.  This facilitates the identification of regions where 
outcomes are either statistically significantly better or worse than would be 
expected based on the characteristics of their population with diabetic foot 
disease (see Figure 4.2 below).   
 
Figure 4.2: Risk adjusted outcomes: alive and ulcer free at 12 weeks, taken from 
the National Diabetes Footcare Audit Fourth Annual Report 
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Chapter 5: Longitudinal cohort of people presenting with diabetic 
foot ulcers in northern England  
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Introduction 
 
The role of hyperglycaemia in increasing the risk of peripheral vascular disease 
and neuropathy is well documented.  This creates a physiological state in which 
the development and persistence of foot ulcers is increased and lifetime risk of 
an individual with diabetes developing a foot ulcer is estimated to be 25% [99].  
This results in a considerable burden to the healthcare provider, with annual 
costs estimated to be £580 million per annum in England [100], and to the 
individual.  There is a need to understand the morbidity and mortality of people 
presenting with diabetic foot ulcers using contemporary data ‘real world’ data 
on people with diabetic foot disease outside specific research trials.  This 
population based study examines the characteristics and outcomes of people 
with incident diabetic foot ulcers in a longitudinal cohort of people presenting 
with diabetic foot ulcers in Salford in the north of England.   
 
Methods 
 
Since 2001 data on all people presenting to the multi-disciplinary foot care team 
with an incident diabetic foot ulcer in the city of Salford, England has been 
recorded in an electronic system as part of routine clinical practice.  This 
recorded the patient’s age, details of the presenting ulcer (the main site of the 
ulcer, whether cellulitis was present, whether the ulcer extended to the bone 
and whether there was evidence of peripheral vascular disease) and time to 
ulcer healing.  A cohort of people presenting between 1st January 2001 and 31st 
December 2012 was identified.  Records for these individuals have been linked to 
complementary primary and secondary care electronic health records using the 
unique National Health Service number to identify type of diabetes, 
cardiovascular risk factors (HbA1c, blood pressure, cholesterol, body mass index, 
kidney function as measured by eGFR, smoking status) and death registrations to 
June 2013.   
 
An ulcer severity score (range 0 to 4) was created with one point being allocated 
for the ulcer being on the hind foot, cellulitis being present, the ulcer extending 
to the bone and having evidence of peripheral vascular disease. This is as close 
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an approximation of the SINBAD score [84] as possible considering the dataset 
collated.  
 
Statistical analysis 
Changes over time in the mean age at presentation of incident foot ulcer and the 
mean ulcer severity score were assessed using one way ANOVA tests.  
Differences in the proportion of the cohort that were male and who had a 
previously healed ulcer were tested using chi-square statistics.  Mortality rates 
standardised to the European Standard Population were calculated for one year 
and two years from initial presentation of a foot ulcer.  Confidence intervals for 
standardised mortality rates were computed using the Exact method [101].  
Logistic regression models were created to assess the predictive factors for the 
ulcer healing within 90 days of first presentation.  Cox regression models were 
constructed to explore the relationship between patient characteristics, the 
nature of the presenting ulcer, known cardiovascular risk factors and survival. 
 
Results  
 
Between 2001 and 2012 there were 8028 incident cases of diabetic foot ulcers 
among 2937 people.  There has been no change in age at presentation (mean 
68.6 years, median 70 years) or the proportion of patients that were male 
(59.4%).  2.4% of incident ulcers were deep enough to involve the bone, 24.0% 
were accompanied by cellulitis and 32.7% were in people with peripheral 
vascular disease.  The mean ulcer severity score fell from 1.04 in 2001 to 0.76 in 
2012 (p<0.005).  This was accompanied by a change in ulcer characteristics.  The 
percentage of ulcers that were deep enough to reach the bone and were on the 
rear foot remained relatively constant over time whilst the proportion of people 
presenting with peripheral vascular disease fell from 48.8% in 2001 to 28.8% in 
2012 (p<0.005).  The proportion of people reporting a previously healed foot 
ulcer reduced from 67.2% in 2001 to 44.6% in 2012 (p<0.005).   
 
  
87 
 
Figure 5.1: Characteristics of ulcers over time 
 
 
Median time to healing was 79 days (IQR 21-320 days) and 45.1% healed within 90 
days.  Men (OR 0.87 95% CI 0.77-0.98) and older people (OR 1.01 95% CI 1.00-
1.01 per additional year) were less likely to heal within 90 days.  Having 
peripheral vascular disease (OR 0.75, 95% CI 0.66-0.85), cellulitis (OR 0.84, 95% 
CI 0.74-0.96), an ulcer to the bone (OR 0.46, 95% CI 0.30-0.70) were significantly 
associated with a lower chance of the incident ulcer healing within 90 days 
whilst having a previously healed ulcer increased the chance of healing (OR 1.53, 
95% CI 1.36-1.71).   
 
The foot care records of 1728 (58.0%) individuals could be linked to their general 
health record to provide sufficient data for analysis.  Age (OR 0.99 per additional 
year of age, 95% CI 0.98-0.99) and being male (OR 0.74 95% CI 0.60-0.92), 
increased depth (probing to bone) (OR 0.22 95% CI 0.08-0.60), rear foot location 
(OR 0.68 95% CI 0.49-0.92), peripheral vascular disease (OR 0.52 95% CI 0.39-
0.69) and blood pressure below the current NICE recommended target for people 
with vascular disease (130/80) (OR 0.64 95% CI 0.51-0.79) were associated with a 
lower chance of healing in 90 days.  Total cholesterol below 5mmol/l was linked 
with ulcer healing (OR 1.20 95% CI 1.01-1.41) in 90 days, whereas kidney 
function was inversely related to the chance of healing in 90 days (OR compared 
to eGFR 90+ for eGFR 60-89 1.27 95% CI 1.01-1.60, eGFR 30-59 1.71 95 CI 1.19-
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2.47, eGFR <30 4.57 95% 0.52-39.92) (see Figure 5.1). Cellulitis, type of 
diabetes, HbA1c, body mass index and smoking were not associated with ulcer 
healing rates at 90 days.   
 
Figure 5.2: Odds ratios associated with ulcer healing within 90 days 
 
 
 
In this cohort crude mortality one year from initial presentation was 13.1% and 
19.5% at two years.  Age and sex standardisation to the European Standard 
Population adjusted one year mortality to 63.5 (95% CI 51.0-77.4) per 1000 
person years for men and 47.3 (95% CI 38.9-56.6) per 1000 person years for 
women.  Over the time period studied there was a non-statistically significant 
decline in morality.  For those presenting with incident foot ulcers in the final 
three years of the data collection (2010 to 2012) one year standardised mortality 
rates were 52.2 (95% CI 35.1-74.0) per 1000 person years for males and 40.4 
(23.7-62.8) per 1000 person years for females.  This compares to 92.3 (95% CI 
48.6-144.0) per 1000 person years and 59.7 (95%CI 44.9-77.4) per 1000 person 
years for men and women respectively between 2001 and 2003.  A higher ulcer 
severity score was associated with shorter survival (see Figure 5.2).  
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Figure 5.3: Survival by ulcer severity score 
 
Increasing age (HR 1.10 per additional year of age, 95% CI 1.09-1.11) and being 
male (HR 1.31 95% CI 1.08-1.60) were significantly associated with shorter 
survival.  Peripheral vascular disease (HR 1.61 95% CI 1.30 - 1.99) and rear foot 
ulcers (HR 1.72 95% CI 1.35 - 2.20) were also significantly associated with shorter 
survival.  Smokers had significantly higher mortality than those who had never 
smoked (HR 1.71 95% CI 1.30 – 2.25) whilst ex-smokers showed a non-significant 
raised risk of dying (HR 1.19 95% CI 0.97 - 1.47).  Blood pressure below 130/80 
was associated with higher mortality (HR 1.39 95% CI 1.15 - 1.69).  Poor kidney 
function was associated with higher mortality but only reached statistical 
significance with very advanced disease (eGFR<15 (OR 9.71 95% 2.38-39.64) (see 
Figure 5.3). The depth of the incident ulcer and cellulitis, type of diabetes, 
HbA1c, body mass index and lipid profile were not significantly associated with 
differential mortality. 
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Figure 5.4: Hazard ratios associated with risk of dying 
 
 
 
Discussion 
 
This analysis represents a contemporary study examining the characteristics and 
outcomes of people presenting with diabetic foot ulcers.  It uses data that was 
routinely collated as part of clinical practice to chart the change in 
characteristics of people presenting with diabetic foot ulcers in Salford since 
2001.  There have been several studies that have documented the decline in 
lower limb amputations among people with diabetes over a similar time period 
[24].  Whilst the occurrence of lower limb amputations is often used as a 
measure of outcome when considering foot health in people with diabetes, 
surgery (whether resulting in amputation or not) is a treatment rather than a 
patient centred outcome and subject to variation in surgical practice and culture 
that cannot be fully explained by differences in presenting patients [79,102].  
Assessing ulcer healing and mortality provides a more holistic picture of 
outcomes for the cohort studied.   
 
In this cohort just under half of ulcers healed within 12 weeks.  This is similar to 
the ulcer healing rate of 49.4% within 90 days reported in the pilot study 
collating data from 23 multi-disciplinary foot care teams across England [103].  It 
is also similar to the proportion of people reported to be alive and ulcer free 12 
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weeks after initial presentation (48.2%) in the 22,653 cases analysed in the most 
recent National Diabetes Footcare Audit for England and Wales [104].   
 
Whilst the demographic characteristics of those presenting with diabetic foot 
ulcers has not changed over the time period studied, the overall severity of the 
ulcers at presentation to a multi-disciplinary foot team is lower.  One possible 
explanation for this is a growing understanding amongst people with diabetes 
and non-foot specialist health professionals of the importance of early 
identification of foot ulcers and prompt referral to multi-disciplinary foot care 
teams.  The clear decline in the number of ulcers where peripheral vascular 
disease is present suggests that the general aim of reducing cardiovascular risk 
in people with diabetes has altered the characteristics of foot ulcers at 
presentation.   
 
The short term mortality of people presenting with diabetic foot disease was 
high with almost one in five dying in the following two years.  This death rate is 
partly a reflection of the age of people with incident diabetic foot ulcers and is 
comparable with a study of 185 people with incident diabetic foot ulcers 
presenting in Liverpool between 1994 and 1998 which reported 19.5% mortality 
after two years and 44% after five years [105].  A larger, more recent analysis of 
20,737 people developing a diabetic foot ulcer reported a similar five year 
mortality risk (42%) [106].  However, given the average age of people presenting 
with diabetic foot ulcers high crude mortality rates are to be expected and age 
standardisation is needed to make meaningful comparisons.  After age 
standardisation one year mortality in this cohort of people with diabetic foot 
ulcers in Salford was still high at 51.5 and 41.7 deaths per 1000 person years for 
males and females respectively for the period 2010 to 2012.  This is similar to 
41.5 per 1000 person years in a cohort resident in Cheshire, England who were 
followed up from 2004 to 2015 [106]. Comparisons between the mortality 
experienced by those presenting with diabetic foot ulcers and the general 
population are stark.  One year mortality rates of 8.1 deaths per 1000 person 
years for men and 5.7 deaths per 1000 person years for women in the general 
population of Salford over the same three years (2010-2012) [107] meaning that 
people presenting with diabetic foot ulcers are approximately seven times more 
likely to die in the twelve months following presentation to the multi-
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disciplinary foot care team than their local peers in the general population.  
They also have approximately five times the risk of death for all people with 
diagnosed diabetes living in Salford [55].  These findings of increased risk of 
dying illustrate the poor outcomes faced by people at the time of presentation 
with a diabetic foot ulcer.   
 
In this cohort having an ulcer on the hind foot, peripheral vascular disease, 
smoking (either currently or in the past) and poor kidney function were 
associated with a greater risk of dying.  Similar risk factors (peripheral 
ischaemia, ulcer size and depth and the presence of neuropathy) for not being 
alive and ulcer free 12 weeks after initial presentation have been identified by 
the National Diabetes Footcare Audit [104].  Further insight into mortality risk 
amongst people with diabetic foot ulcers would be gleaned by considering the 
cause of death and potential interactions between the ulcer and pre-existing co-
morbidities.   
 
This data provides a comprehensive picture of the characteristics and outcomes 
of people presenting with diabetic foot ulcers in Salford over a ten year period.  
However, this data is limited to a specific geographical area covered by a 
particular health service.  Previous work has shown that amputations among 
people with diabetes are more common amongst people living in deprived areas 
[108].  Salford is an area with higher than average social deprivation ranking 42nd 
and 26th out of 327 local authorities in England for income deprivation and wider 
deprivation encompassing education, health and living environment respectively 
[109].  It is therefore likely that the incidence and severity of foot ulcers in 
Salford is higher than would be expected compared to national figures.  
Nonetheless, this analysis provides insight that may be applicable across England 
and beyond.  It shows high levels of morbidity and mortality among people 
presenting with diabetic foot ulcers.  Given the clear association between 
indicators of poor vascular, renal health and mortality, measures to improve 
outcomes amongst those with diabetic foot ulcers may need to focus on longer 
term prevention of macro and micro vascular damage.  This is likely to require 
input from across the range of professionals and clinical settings providing care 
for people with diabetes and results will be seen over the medium to long term. 
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Update 
In the period since this chapter was produced the National Diabetes Footcare 
Audit has been established and matured to provide meaningful data on the 
characteristics, care and short term outcomes of people with diabetic foot ulcers 
(see previous chapter).  A similar study of people presenting with diabetic foot 
ulcers between 2003 and 2017 to South Devon community podiatry service and 
Torbay Hospital Multi-Disciplinary Foot Team has been published [110].  In line 
with the analysis in this thesis, it reports that there has not been a change in the 
age or sex of people presenting with diabetic foot ulcers but the proportion 
where peripheral vascular disease is evident has declined.  It is worth noting that 
the mean age of presentation in this cohort (76.2 years old between 2013-17 
compared to 68.6 years in Salford).  This may be a reflection of the higher level 
of social deprivation in Salford compared to South Devon and the association 
between social deprivation and a greater risk of developing foot disease and at 
younger ages. It also found high absolute mortality rates with 10 year survival of 
69.8% among those aged less than 65 years old rising to 5.1% in those aged 81 or 
older at first presentation. Given the higher mean age at presentation in this 
study greater absolute mortality is to be expected and full adjustment for age, 
comorbidity and ulcer characteristics would be needed to provide a more 
meaningful comparison.   
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Chapter 6: Association between routine care processes completion 
and mortality in people with diabetes: Analysis of data from the 
National Diabetes Audit for England 
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Introduction 
 
There is robust evidence that blood glucose control, blood pressure control 
reduce both the microvascular and macrovascular complications of diabetes, 
with blood lipid control lowering macrovascular outcomes [111–113].  
Accordingly treatment target goals for glycaemic control as measured by HbA1c 
levels, for blood pressure and for lipid levels are at the centre of every national 
and international diabetes care guideline [43,114,115]. 
 
In order to know whether these treatment targets have been reached and to 
review treatment they need to be measured.  Their measurement, along with 
review of weight and smoking behaviour plus surveillance for early detection of 
complications (kidney disease, foot and eye), have in the United Kingdom been 
called the core nine diabetes care processes.  The National Institute for Health 
and Clinical Excellence recommends that people with Type 1 [42] and Type 2 
[43] diabetes are offered these nine care processes annually (measurement of 
HbA1c, blood pressure, cholesterol, body mass index, creatinine and urinary 
albumin, digital retinal examination, foot examination for sensory and 
circulatory impairment, and recording of smoking status).  
 
While most international and national diabetes guidelines stress the importance 
of measuring these care processes the level of evidence to support this 
recommendation is usually not stated or, when it is, rated at the lowest standard 
of evidence i.e. that of “expert consensus” or “clinical experience” [115].  This 
reflects the fact that little has been published about whether or not care process 
completion is itself (causally) related to any of the final outcomes of diabetes 
such as micro and macro vascular complications and mortality or whether it is 
just a vehicle to support treatment target achievement. 
 
In England and Wales, the National Diabetes Audit (NDA) has, every year since 
2004, collected information from general and specialist electronic records on the 
rates of achievement of these care processes by provider organisation and 
published this information annually.  Using routinely recorded patient level data 
from the NDA this analysis aims to assess whether the specific healthcare 
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activity of annual care processes completion is associated with the most final 
diabetes outcome, mortality. 
 
Methods 
 
The National Diabetes Audit extracts and combines electronic patient record 
data on people with diagnosed diabetes from primary and secondary care 
services annually.  This routinely recorded data is collated to create a database 
of patient demographic characteristics (age, sex, ethnic group, social 
deprivation, type and duration of diabetes) and the annual occurrence and 
outcome of care processes (HbA1c, blood pressure, total cholesterol, creatinine, 
urinary albumin, body mass index, smoking status, foot examination and eye 
examination). During the period studied it did not include any medication data. 
 
A cohort was identified of people with Type 1 or Type 2 diabetes registered with 
an English health provider, and included in all three of the National Diabetes 
Audit collections for the periods January 2008 to March 2009, January 2009 to 
March 2010 and January 2010 to March 2011 and still alive on 1st April 2011.  
Individuals without valid age or sex records were excluded from the analysis.  
Type of diabetes was identified as that most recently recorded.  The mean 
number of care processes received per year across these three data collection 
periods was calculated for each individual.  An individual was classified as 
receiving a care process if it had been recorded as being undertaken within the 
specified periods irrespective of the result obtained or recorded.  Mean values 
for HbA1c, systolic blood pressure, diastolic blood pressure, total cholesterol and 
body mass index were calculated for the same three-year period.  The cohort 
was matched to Office for National Statistics death registrations to identify 
mortality up to 31st December 2015.  Deaths were classified as having a primary 
cause of cardiovascular disease (ICD-10 codes I01-I99) and non-cardiovascular 
disease (all ICD-10 codes except I01-I99).  Home postcodes were used to link to 
the Indices of Multiple Deprivation [109] to derive an area based measure of 
social deprivation.   
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Statistical analysis  
Cox regression models were created to investigate the association between 
mortality and the average number of care processes received after adjusting for  
• Age and sex 
• Age, sex, ethnic group, social deprivation and smoking status 
• Age, sex, ethnic group, social deprivation, smoking status, HbA1c, systolic 
blood pressure, diastolic blood pressure, total cholesterol and body mass 
index 
 
All variables except age were analysed as categorical variables to allow the non-
linear associations between risk factors and mortality to be included in the 
models.  An additional category of ‘missing data’ was also included for each 
variable except age and sex to take account of the fact that people who had not 
received a care process would not have a valid measurement of the outcome or 
risk factor. 
 
Separate models were calculated for deaths due to cardiovascular disease and 
those due to non-cardiovascular disease.  To investigate whether the 
relationship between care processes and mortality varied by ethnic group 
separate models were produced for people from white ethnic groups (White 
British, White Irish and White ‘other’ groups), from south Asian ethnic groups 
(Indian, Pakistani and Bangladeshi) and from Black ethnic groups (Black African 
and Black Caribbean).  Given its importance to future risk of mortality, models 
were also created for individuals stratified into quintiles based on social 
deprivation.   
 
Results 
 
A total of 215,101 people with Type 1 diabetes and 2,182,409 people with Type 
2 diabetes were identified within the three data collections.  534 (0.2%) people 
with Type 1 diabetes and 4269 (0.2%) people with Type 2 diabetes were 
excluded due to a lack of a valid age or sex recorded.  Over the follow up period 
there were 22,084 deaths (10.3%) amongst those with Type 1 diabetes and 
463,365 (21.2%) deaths in those with Type 2 diabetes.   
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After adjusting for age and sex, completing less than five care processes per 
year compared to completing all nine care processes was associated with a 
higher risk of dying from all causes (Hazard ratio (HR) 2.22 (95% CI 2.12-2.32) for 
those with Type 1 diabetes and 2.16 (95% CI 2.14-2.18) for those with Type 2 
diabetes) (see Table 6.1 and Figures 6.1a. 6.1b).  The additional risk of 
mortality reduces as the mean number of care processes completed increases for 
people with both Type 1 and Type 2 diabetes.  Adjusting for demographic 
characteristics (age, sex, ethnic group, deprivation and smoking status) and 
cardiovascular risk factors (HbA1c, blood pressure, total cholesterol and body 
mass index) attenuated the hazard ratio associated with a mean of less than five 
care processes per year to 1.71 (95% CI 1.62-1.82) for those with Type 1 diabetes 
and to 1.71 (95% CI 1.68-1.73) for those with Type 2 diabetes.   
 
Table 6.1: Hazard ratios for mortality from all causes associated with mean 
number of care processes received per year by type of diabetes  
 Type 1 diabetes Type 2 diabetes 
Number included in analysis 214,567 2,182,409 
Number of events (deaths) 22,084 463,365 
Adjusted for age and sex <5 2.22 (2.12-2.32) 2.16 (2.14-2.18) 
5-5.9 1.87 (1.76-1.98) 1.84 (1.81-1.86) 
6-6.9 1.73 (1.64-1.82) 1.61 (1.6-1.63) 
7-7.9 1.36 (1.3-1.42) 1.34 (1.33-1.35) 
8-8.9 1.05 (1.01-1.1) 1.06 (1.05-1.07) 
9 Reference group  Reference group  
Adjusted for age, sex, 
ethnic group, deprivation 
and smoking status 
<5 2.26 (2.16-2.37) 2.09 (2.07-2.12) 
5-5.9 1.85 (1.74-1.96) 1.84 (1.82-1.87) 
6-6.9 1.74 (1.65-1.83) 1.63 (1.61-1.65) 
7-7.9 1.37 (1.31-1.43) 1.35 (1.34-1.36) 
8-8.9 1.08 (1.03-1.12) 1.07 (1.06-1.07) 
9 Reference group  Reference group  
Adjusted for age, sex, 
ethnic group, deprivation, 
smoking status, HbA1c, 
blood pressure, total 
cholesterol and body mass 
index 
<5 1.71 (1.62-1.82) 1.71 (1.68-1.73) 
5-5.9 1.56 (1.47-1.66) 1.6 (1.58-1.63) 
6-6.9 1.56 (1.48-1.64) 1.49 (1.47-1.5) 
7-7.9 1.29 (1.23-1.35) 1.29 (1.27-1.3) 
8-8.9 1.05 (1.01-1.1) 1.05 (1.05-1.06) 
9 Reference group  Reference group  
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Figure 6.1a: Hazard ratios for mortality from all causes associated with mean 
number of care processes received per year, Type 1 diabetes 
 
Figure 6.1b: Hazard ratios for mortality from all causes associated with mean 
number of care processes received per year, Type 2 diabetes 
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Associations between missing data and mortality varied across the variables used 
to adjust for confounding in the survival models.  Not having a valid home 
postcode recorded (and therefore missing data on social deprivation) was 
associated with the highest hazard ratios for death (HR 3.15 95% CI 1.92-5.14 for 
Type 1 diabetes and 2.31 95% CI 2.08-2.56 for Type 2 diabetes) (see Table 6.2).  
Missing data on ethnic group, body mass index and total cholesterol were also 
associated with higher risks of mortality for people with Type 1 and Type 2 
diabetes.   
 
Table 6.2: Hazard ratios for mortality from all causes by type of diabetes 
 Type 1 diabetes Type 2 diabetes 
n (deaths) 214,567 (22,084) 
2,182,409 
(463,365) 
Age (per additional year) 1.08 (1.08-1.08) 1.09 (1.08-1.09) 
Male  1.22 (1.18-1.25) 1.19 (1.18-1.19) 
Social 
deprivation 
Most deprived 1.56 (1.49-1.63) 1.3 (1.29-1.31) 
2nd most deprived 1.37 (1.32-1.44) 1.18 (1.17-1.19) 
3rd most deprived 1.2 (1.15-1.26) 1.11 (1.1-1.12) 
2nd least deprived 1.12 (1.07-1.17) 1.05 (1.04-1.07) 
Least deprived Reference group  Reference group  
Missing data 3.15 (1.92-5.14) 2.31 (2.08-2.56) 
Ethnic group White Reference group  Reference group  
Mixed 0.95 (0.81-1.12) 0.68 (0.65-0.71) 
South Asian 0.86 (0.79-0.93) 0.66 (0.65-0.67) 
Black 0.72 (0.65-0.78) 0.6 (0.59-0.62) 
Other 0.98 (0.9-1.08) 0.85 (0.84-0.87) 
Missing data 1.28 (1.23-1.32) 1.31 (1.3-1.32) 
Smoking status Current smoker 1.7 (1.64-1.76) 1.72 (1.71-1.74) 
Previous smoker 1.16 (1.12-1.2) 1.2 (1.19-1.21) 
Non-smoker, unknown 
history 1.28 (1.23-1.34) 1.37 (1.35-1.38) 
Never smoked Reference group  Reference group  
Missing data 0.93 (0.85-1.01) 1.38 (1.35-1.4) 
HbA1c 
(mmol/mol) 
<48 1.26 (1.19-1.34) 1.07 (1.06-1.08) 
48-52 1.05 (0.98-1.12) 0.95 (0.94-0.96) 
53-57 Reference group Reference group  
58-63 0.99 (0.94-1.05) 1.09 (1.07-1.1) 
64-68 1 (0.94-1.06) 1.18 (1.16-1.2) 
69-74 1.04 (0.98-1.1) 1.28 (1.26-1.3) 
75-79 1.17 (1.1-1.25) 1.32 (1.29-1.34) 
80+ 1.54 (1.46-1.62) 1.56 (1.54-1.58) 
Missing data 1.17 (1.08-1.28) 0.91 (0.9-0.93) 
Systolic blood 
pressure 
(mmHg) 
<100 1.3 (1.24-1.36) 1.45 (1.44-1.47) 
100-119 1.08 (1.03-1.12) 1.13 (1.12-1.13) 
120-139 Reference group Reference group  
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140-159 1.04 (0.99-1.08) 1.01 (1-1.02) 
160-179 1.18 (1.12-1.25) 1.09 (1.08-1.11) 
180+ 1.47 (1.38-1.57) 1.25 (1.23-1.27) 
Missing data 0.59 (0.33-1.05) 1.44 (1.22-1.69) 
Diastolic blood 
pressure 
(mmHg) 
<70 1.05 (1-1.09) 1.16 (1.15-1.18) 
70-79 0.93 (0.89-0.97) 1.02 (1.01-1.02) 
80-89 Reference group Reference group 
90-99 1.13 (1.04-1.24) 1.05 (1.03-1.07) 
100+ 1.53 (1.3-1.81) 1.21 (1.16-1.26) 
Missing data 1.31 (0.74-2.34) 0.63 (0.54-0.75) 
Total 
cholesterol 
<4mmol/l Reference group Reference group  
4-4.9mmol/l 0.83 (0.81-0.86) 0.89 (0.88-0.89) 
5+mmol/l 0.93 (0.9-0.97) 0.88 (0.87-0.88) 
Missing data 1.1 (1.03-1.18) 1.14 (1.12-1.16) 
Body mass index 
(kg/m2) 
<18.5 2.62 (2.4-2.86) 2.01 (1.96-2.06) 
18.5-24.9 1.25 (1.21-1.3) 1.27 (1.26-1.28) 
25-29.9 Reference group Reference group  
30-34.9 1.14 (1.09-1.18) 1 (0.99-1.01) 
35-39.9 1.4 (1.33-1.49) 1.11 (1.1-1.12) 
40+ 1.83 (1.71-1.97) 1.48 (1.46-1.5) 
Missing data 1.62 (1.53-1.72) 1.53 (1.51-1.55) 
Mean care 
processes 
received 
<5 1.71 (1.62-1.82) 1.71 (1.68-1.73) 
5-5.9 1.56 (1.47-1.66) 1.6 (1.58-1.63) 
6-6.9 1.56 (1.48-1.64) 1.49 (1.47-1.5) 
7-7.9 1.29 (1.23-1.35) 1.29 (1.27-1.3) 
8-8.9 1.05 (1.01-1.1) 1.05 (1.05-1.06) 
9 Reference group  Reference group  
 
Amongst people with Type 1 diabetes the association between less than five care 
processes and additional risk of death was lower for death due to cardiovascular 
disease than for deaths from all other causes (HR 1.50 95% CI 1.36-1.67 
compared to 1.83 95% CI 1.70-1.97) (see Table 6.3).  A similar pattern was found 
in people with Type 2 diabetes where the hazard ratio associated with a mean of 
less than five care processes per year is 1.61 (95% CI 1.57-1.65) for deaths with a 
primary cause of cardiovascular disease and 1.76 (95% CI 1.73-1.79) for death 
with a primary cause of non-cardiovascular disease.   
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Table 6.3: Hazard ratios for mortality from all causes associated with mean 
number of care processes received per year by type of diabetes and primary 
cause of death 
Mean care processes Type 1 diabetes Type 2 diabetes 
Cardiovascular 
disease 
<5 1.50 (1.36-1.67) 1.61 (1.57-1.65) 
5-5.9 1.51 (1.36-1.67) 1.52 (1.48-1.56) 
6-6.9 1.47 (1.34-1.6) 1.42 (1.39-1.45) 
7-7.9 1.25 (1.16-1.35) 1.26 (1.24-1.28) 
8-8.9 1.02 (0.96-1.09) 1.05 (1.04-1.07) 
9 
Reference 
group Reference group 
Non-cardiovascular 
disease 
<5 1.83 (1.7-1.97) 1.76 (1.73-1.79) 
5-5.9 1.6 (1.48-1.72) 1.65 (1.62-1.68) 
6-6.9 1.61 (1.51-1.72) 1.52 (1.5-1.54) 
7-7.9 1.32 (1.25-1.4) 1.3 (1.28-1.31) 
8-8.9 1.07 (1.02-1.13) 1.05 (1.05-1.06) 
9 
Reference 
group Reference group 
After adjustment for age, sex, social deprivation, ethnic group, smoking status, HbA1c, 
systolic and diastolic blood pressure, cholesterol and body mass index. 
 
The additional risk of dying associated with fewer achieved care processes was 
higher among people living in more deprived neighbourhoods compared to their 
peers in less deprived areas (see Table 6.4).   
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Table 6.4: Hazard ratios for mortality from all causes associated with mean 
number of care processes received per year by type of diabetes and 
deprivation quintile 
Mean number of care processes Type 1 diabetes Type 2 diabetes 
Least deprived  <5 1.58 (1.4-1.79) 1.62 (1.58-1.67) 
5-5.9 1.45 (1.29-1.64) 1.59 (1.55-1.64) 
6-6.9 1.55 (1.39-1.73) 1.52 (1.49-1.56) 
7-7.9 1.28 (1.16-1.41) 1.31 (1.29-1.34) 
8-8.9 1.12 (1.02-1.22) 1.07 (1.05-1.09) 
9 Reference group Reference group 
2nd least 
deprived 
<5 1.39 (1.23-1.59) 1.61 (1.56-1.67) 
5-5.9 1.46 (1.29-1.66) 1.58 (1.53-1.63) 
6-6.9 1.44 (1.28-1.61) 1.45 (1.41-1.49) 
7-7.9 1.3 (1.18-1.43) 1.31 (1.28-1.33) 
8-8.9 1.08 (0.99-1.18) 1.05 (1.03-1.06) 
9 Reference group Reference group 
3rd most 
deprived 
<5 1.91 (1.67-2.17) 1.67 (1.62-1.73) 
5-5.9 1.77 (1.55-2.02) 1.56 (1.51-1.61) 
6-6.9 1.59 (1.42-1.78) 1.48 (1.44-1.52) 
7-7.9 1.25 (1.13-1.38) 1.28 (1.25-1.31) 
8-8.9 0.98 (0.9-1.07) 1.05 (1.03-1.07) 
9 Reference group Reference group 
2nd most 
deprived 
<5 1.94 (1.68-2.23) 1.85 (1.78-1.91) 
5-5.9 1.65 (1.43-1.89) 1.66 (1.61-1.72) 
6-6.9 1.66 (1.48-1.87) 1.49 (1.45-1.53) 
7-7.9 1.37 (1.24-1.52) 1.27 (1.24-1.3) 
8-8.9 1.03 (0.94-1.13) 1.04 (1.03-1.06) 
9 Reference group Reference group 
Most deprived <5 2.08 (1.79-2.42) 1.89 (1.82-1.96) 
5-5.9 1.65 (1.41-1.92) 1.66 (1.6-1.72) 
6-6.9 1.64 (1.43-1.88) 1.49 (1.44-1.53) 
7-7.9 1.3 (1.16-1.46) 1.25 (1.22-1.28) 
8-8.9 1.09 (0.98-1.2) 1.06 (1.04-1.08) 
9 Reference group Reference group 
After adjustment for age, sex, ethnic group, smoking status, HbA1c, systolic and 
diastolic blood pressure, cholesterol and body mass index. 
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In the most deprived fifth of neighbourhoods the fully adjusted hazard ratio 
associated with a mean of less than five care processes was 2.08 (95% CI 1.79-
2.42) for those with Type 1 diabetes and 1.89 (95% CI 1.82-1.96) for those with 
Type 2 diabetes.  By comparison the equivalent hazard ratios for people living in 
the least deprived areas are 1.58 (95% CI 1.40-1.79) for Type 1 diabetes and 1.62 
(95% CI 1.58-1.67) for Type 2 diabetes.   
 
There were also statistically significant differences by ethnic group. For each 
ethnic group fewer achieved care processes were associated with an increased 
risk of mortality (see Table 6.5).   
 
Table 6.5: Hazard ratios for mortality from all causes associated with mean 
number of care processes received per year by type of diabetes and ethnic 
group 
Mean number of care processes Type 1 diabetes Type 2 diabetes 
White ethnic groups <5 1.82 (1.69-1.95) 1.87 (1.83-1.9) 
5-5.9 1.62 (1.51-1.74) 1.65 (1.62-1.68) 
6-6.9 1.6 (1.5-1.7) 1.53 (1.51-1.55) 
7-7.9 1.32 (1.25-1.39) 1.33 (1.32-1.35) 
8-8.9 1.08 (1.03-1.13) 1.08 (1.07-1.09) 
9 Reference group  Reference group  
South Asian ethnic 
groups 
<5 1.1 (0.77-1.58) 1.13 (1.06-1.22) 
5-5.9 1.5 (1.06-2.1) 1.24 (1.16-1.33) 
6-6.9 0.94 (0.67-1.33) 1.26 (1.19-1.34) 
7-7.9 0.91 (0.69-1.21) 1.15 (1.1-1.21) 
8-8.9 0.79 (0.63-1) 1 (0.96-1.04) 
9 Reference group  Reference group  
Black ethnic groups <5 1.32 (0.85-2.04) 1.42 (1.29-1.56) 
5-5.9 1.65 (1.11-2.46) 1.65 (1.51-1.82) 
6-6.9 1.76 (1.22-2.54) 1.37 (1.26-1.49) 
7-7.9 1.88 (1.38-2.56) 1.31 (1.22-1.41) 
8-8.9 1.19 (0.89-1.6) 1.09 (1.03-1.15) 
9 Reference group  Reference group  
After adjustment for age, sex, social deprivation, smoking status, HbA1c, systolic and 
diastolic blood pressure, cholesterol and body mass index. 
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However, for people from White ethnic groups a mean of less than five care 
processes per year was associated with a greater additional risk of dying (HR 
1.82 95% CI 1.69-1.95 for Type 1 diabetes, 1.87 95% CI 1.83-1.90 for Type 2 
diabetes) than for those from south Asian ethnic groups (HR 1.10 95% CI 0.77-
1.58 for Type 1 diabetes, HR 1.13 95% CI 1.06-1.22 for Type 2 diabetes) or from 
Black ethnic groups (HR 1.32 95% CI 0.85-2.04 for Type 1 diabetes, HR 1.42 95% 
CI 1.29-1.56 for Type 2 diabetes).   
 
Discussion 
 
In this large cohort of people with Type 1 and Type 2 diabetes individuals with a 
low number of achieved annual care processes had higher medium term 
mortality compared to those in whom all nine NICE recommended annual care 
processes were completed.  People who received fewer annual care processes 
had a higher risk of dying over the medium term.  However, after adjusting for 
treatment related factors known to increase complications risk (HbA1c, blood 
pressure, cholesterol and body mass index) and for missing data associated with 
not receiving care processes the additional risk of mortality, although 
attenuated, remained statistically and clinically significant. This suggests that 
the basic interactions with healthcare providers required to deliver the care 
processes in some way confer important health benefit over and above their role 
in identification and management of cardiovascular risk factors. In fact, the 
association between receiving fewer care processes and higher mortality was 
stronger for deaths due to non-cardiovascular disease than for cardiovascular 
disease further implying that these healthcare provider interactions may have 
positive benefits beyond better cardiovascular risk management.  Of course, it 
may also be that independent of measured risk factors patients more engaged 
with self-care and lower risk lifestyles attend clinics more often and/or are more 
likely to request the specified care processes on a regular basis. A third possible 
factor is reverse causality, whereby people who do not feel well enough because 
of illness or subclinical illnesses, don’t have the energy to attend all their 
appointments.   
 
There are remarkable similarities between people with Type 1 and Type 2 
diabetes in the direction and scale of the associations identified. In England 
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most people with Type 1 diabetes have specialist led care while for Type 2 
diabetes the majority of people are managed in a primary care setting.  So the 
association seems to be independent of type of diabetes and location of care. 
This would support the idea that it is the intensity of the interaction between 
people with diabetes and their care teams that must in some way influence, or 
mark, the risk of death.  In turn this could be mediated by differences in the 
organisation of care or simply the opportunities for health care professionals and 
people with diabetes to meet, or else it points towards patient characteristics 
(whether more motivated at one end, or less motivated, frailer or with illness at 
the other end) that both lead to less care processes being achieved and at the 
same time to higher risks for CVD or non-CVD deaths. 
 
The association appeared greatest amongst those living in more deprived 
neighbourhoods. Could this suggest that regular patient – healthcare interactions 
compensate for poorer self-efficacy or social support? The even greater risk seen 
in people with no recorded postcode might possibly be due to high 
representation in this group of people who are homeless or in transit 
accommodation such as asylum seekers.  Lack of valid data on ethnic group was 
also associated with higher mortality but poor data on cardiovascular risk was 
not consistently linked to the risk of dying.  This points to well organised and 
structured health care services potentially providing a more proactive, rather 
than reactive, approach to disease management.   
 
The relationship between receipt of care processes and mortality also varies by 
ethnic group, but perhaps not in a manner expected.  The additional risk of 
death amongst those receiving fewest annual care processes was approximately 
80% for a person with Type 2 diabetes with White ethnicity compared to 
approximately 20% for someone with Type 2 diabetes who was of South Asian 
ethnicity.  This may be due to the fact that the association between diabetes, 
hyperglycaemia and mortality varies across ethnic groups.  A recent 
contemporary study using the CPRD cohort reported that the additional risk of 
dying attributable to diagnosed diabetes was actually lower in people from south 
Asian ethnic groups than in those from White ethnic groups [116].  This is despite 
a greater diagnosed incidence of cardiovascular disease amongst people from 
South Asian ethnic groups [117,118].  Thus all-cause mortality has been shown to 
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be lower than in people from White ethnic groups even after adjustment for 
socio-economic status and area of residence [119].  So perhaps this alignment of 
the size of the interaction effect with known ethnic differences in the additional 
risk of death associated with diabetes was to be expected.   
 
Of course, these observational data cannot prove a causal relationship. So, as 
discussed above, the findings could be due to such factors as: accessibility and 
organisation of services; the beneficial effect of more frequent unstructured 
health conversations; or the frequency of organised care planning consultations. 
Equally, it is possible that they are confounded: by associations between poor 
attendance and hazardous behaviours; or an association between poor 
attendances and the prevalence or severity of co-morbidities. What can be 
confidently deduced, however, is that non-attenders for routine diabetes review 
are a group at high risk of mortality over the medium term. It may be that 
making efforts specifically to engage this group would yield worthwhile health 
benefits.  Funders now recognise a need to study such groups more.  
 
The principle strengths of this study are the size of the cohort included in the 
analysis and the fact that it is drawn comprehensively from real world 
healthcare records.  The explicit treatment of missing data is also a strength. 
The suggestion that healthcare interactions are of themselves beneficial would 
have been enhanced if the dataset had been able to exclude the possibility that 
certain medications were used more often in frequent attenders or that co-
morbidities were not over-represented in those having fewer care checks. 
 
This work is the first analysis to consider the association between healthcare 
interactions (the receipt of annual care processes) and medium term health 
outcomes.  So while new and tantalising these observations cannot do more than 
document an association. However, as the association persists even when a 
number of potential confounders are taken into account it implies that the 
organisation of routine care or the personal interactions between health care 
professionals and patients may have an independent and important influence on 
the excess risk of death among people with Type 1 and Type 2 diabetes.  Further 
studies are required to corroborate and extend our findings.  
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Update 
A recent literature review has not identified any further published studies on the 
association between the receipt of care processes or healthcare interactions per 
se (rather than the result of actions to alter risk factors) and medium to long-
term outcomes in people with diabetes.  Further work is still required to 
understand the nature of the association between receiving care process and 
mortality shown here.  Even so, this work should be highly publishable and this 
work will soon be submitted for peer review.  
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Chapter 7: Variation in the risk of mortality in Type 1 and Type 2 
diabetes by age at diagnosis: An analysis of the National Diabetes 
Audit in England 
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Introduction 
Historically, Type 2 diabetes was considered a disease of middle to later life.  
Changes in lifestyle, particularly rises in obesity and physical inactivity, towards 
the end of the twentieth and at the beginning of the twenty-first century 
combined with an understanding that early diagnosis and management of Type 2 
diabetes can improve long term outcomes means that an increasing number of 
people are being diagnosed with the disease in early adulthood.   
A number of studies have found evidence of an additional risk of dying in people 
with Type 2 diabetes diagnosed in early adulthood compared to those diagnosed 
later in life [120–122].  Other studies have suggested that diagnosis of Type 2 
diabetes in early adulthood has a similar association with mortality as Type 1 
diabetes.  However, relatively small cohort sizes and the inclusion of people 
diagnosed with diabetes prior to the big changes in management of Type 2 
diabetes that followed the publication of trials in the late 1990s and early 2000s, 
specifically the impact of lower HbA1c and cardiovascular risk factor 
management (blood pressure and cholesterol) in reducing complications and 
mortality.   
This analysis aims to assess if there are diagnostic age related differences in 
mortality risk between Type 1 and Type 2 diabetes in a large, representative and 
more contemporary ‘real world’ cohort.  
Methods 
The National Diabetes Audit combines data on people with diagnosed diabetes 
from primary and secondary care services.  This provides a database of patient 
characteristics (type of diabetes, age, sex, ethnic group, social deprivation, 
smoking status).  For these people the National Diabetes Audit collates once 
each year the latest valid recorded measurement of HbA1c, blood pressure, total 
cholesterol, body mass index and eGFR in the 15 month period running from 
January to March the following year.  Using NHS numbers and year of birth 
people with Type 1 and Type 2 diabetes aged 20 years or older and recorded in 
the NDA as receiving care from an English NHS care provider after 1st January 
2008 were matched to Office for National Statistics death registrations up to 31st 
December 2015.  The earliest valid records of HbA1c, blood pressure, 
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cholesterol, body mass index and eGFR were identified to give an indication of 
cardiovascular risk as close as possible to diagnosis. 
Statistical analyses  
Cox regression models were created to compare survival between people 
diagnosed at similar ages with Type 1 diabetes and Type 2 diabetes.  These 
models were adjusted for age, sex, smoking status, social deprivation, ethnic 
group, duration of diabetes, HbA1c, total cholesterol, diastolic and systolic 
blood pressure, body mass index and estimated glomerular filtration rate 
(eGFR). 
Sensitivity analyses  
The type of diabetes was identified using the latest recorded type of diabetes 
from healthcare records.  In order to assess the impact of any potential 
misclassification of diabetes type in clinical records sensitivity analyses were 
carried out.  Firstly, all individuals with a diagnosis of Type 1 diabetes where the 
first recorded body mass index was 30 kg/m2 or greater were excluded from 
analysis.  Secondly, all patients with a diagnosis of Type 2 diabetes and a first 
recorded body mass index of less than 25 kg/m2 were removed from the dataset.  
Thirdly, any person excluded from analysis in the two previous sensitivity 
analyses were simultaneously removed from calculations.   
Results 
The analysis included 44,334 people with Type 1 diabetes and 1,754,180 people 
with Type 2 diabetes.  Of those with Type 1 diabetes 25,252 (57.0%) were 
diagnosed between the ages of 20 and 39 years whilst 124,548 (7.1%) of people 
with Type 2 diabetes were diagnosed in the same age range.  The average follow 
up time for those with Type 1 diabetes was 5.8 years and 5.6 years for those 
with Type 2 diabetes.  There were 3178 and 239,649 deaths among those with 
Type 1 and Type 2 diabetes respectively.  Of these 559 were amongst those 
diagnosed with Type 1 diabetes between 20 and 39 years old and 1836 in people 
diagnosed with Type 2 diabetes in the same age group.   
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Amongst those diagnosed aged between 20 and 39 years old those with Type 2 
diabetes had a higher body mass index, were less likely to be from White ethnic 
groups, and more likely to live in socially deprived neighbourhoods.  Those 
diagnosed with Type 1 diabetes were more likely to be current smokers and had 
a higher first recorded HbA1c after diagnosis. As the age of diagnosis increases 
the difference in risk factors between those with Type 1 and Type 2 diabetes 
diminishes (see Table 7.1).    
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Table 7.1: Characteristics and risk factors by age of diagnosis and type of diabetes 
  
Age at diagnosis 
Type 1 diabetes Type 2 diabetes 
20-39 years 40-49 years 50-59 years 60+ years 20-39 years 40-49 years 50-59 years 60+ years 
 n  % n % n % n % N % n % n % n % 
Total   25,252     8,324     5,204     5,554    124,548    272,224     419,859    937,549    
  Male  16,051  63.6%  5,437  65.3%  2,868  55.1%  2,772  49.9% 70,121  56.3%  166,128  61.0%  249,279  59.4% 487,545  52.0% 
Age at start of follow up   
       
  
      
  
  Mean      30.7  
 
   45.8  
 
   55.8  
 
   70.8  
 
      35.4  
 
      46.5  
 
      56.2  
 
     72.1    
Ethnic group   
       
  
      
  
  White  18,251  72.3%  5,863  70.4%  3,642  70.0%  3,806  68.5%    60,543  48.6%  154,726  56.8%  268,468  63.9%  659,922  70.4% 
  Mixed       446  1.8%     109  1.3%       51  1.0%       38  0.7%      2,441  2.0%     4,119  1.5%     4,177  1.0%     5,347  0.6% 
  South Asian    1,209  4.8%     291  3.5%     223  4.3%     217  3.9%    27,586  22.1%    38,074  14.0%    40,740  9.7%  39,923  4.3% 
  Black    1,204  4.8%     451  5.4%     215  4.1%     170  3.1%      9,968  8.0%    19,392  7.1%    18,377  4.4%  25,969  2.8% 
  Other    1,038  4.1%     275  3.3%     185  3.6%     160  2.9%    10,180  8.2%    17,192  6.3%    19,899  4.7%  26,466  2.8% 
  Missing    3,104  12.3%  1,335  16.0%     888  17.1%  1,163  20.9%    13,830  11.1%    38,721  14.2%    68,198  16.2% 179,922  19.2% 
IMD   
       
  
      
  
  Most deprived    6,730  26.7%  1,967  23.6%  1,128  21.7%  1,074  19.3%    46,721  37.5%    85,754  31.5%  108,334  25.8%  188,934  20.2% 
  2nd most deprived    5,870  23.2%  1,765  21.2%  1,056  20.3%  1,086  19.6%    31,227  25.1%    64,415  23.7%    92,106  21.9% 189,626  20.2% 
  3rd most deprived    4,861  19.2%  1,656  19.9%  1,060  20.4%  1,198  21.6%    20,845  16.7%    49,240  18.1%    81,669  19.5% 197,441  21.1% 
  2nd least deprived    4,113  16.3%  1,507  18.1%     985  18.9%  1,129  20.3%    14,436  11.6%    39,352  14.5%    73,099  17.4% 191,634  20.4% 
  Least deprived    3,653  14.5%  1,422  17.1%     968  18.6%  1,060  19.1%    11,221  9.0%    33,313  12.2%    64,394  15.3% 169,179  18.0% 
  Missing        25  0.1%        7  0.1%        7  0.1%        7  0.1%          98  0.1%        150  0.1%        257  0.1%       735  0.1% 
Body mass index at start   
       
  
      
  
  <18.5       742  2.9%     157  1.9%       87  1.7%     101  1.8%        418  0.3%        571  0.2%        920  0.2%  6,480  0.7% 
  18.5-24.9  10,176  40.3%  2,584  31.0%  1,443  27.7%  1,354  24.4%    11,753  9.4%    19,768  7.3%    31,605  7.5% 128,228  13.7% 
  25-29.9    8,031  31.8%  2,897  34.8%  1,709  32.8%  1,808  32.6%    30,102  24.2%    68,444  25.1%  118,484  28.2% 335,008  35.7% 
  30-34.9    3,191  12.6%  1,479  17.8%  1,029  19.8%  1,211  21.8%    31,057  24.9%    78,087  28.7%  130,650  31.1% 266,171  28.4% 
  35-39.9    1,130  4.5%     584  7.0%     443  8.5%     453  8.2%    22,742  18.3%    52,565  19.3%    75,242  17.9% 113,064  12.1% 
  40+       660  2.6%     336  4.0%     253  4.9%     210  3.8%    24,471  19.6%    46,839  17.2%    54,050  12.9%  53,834  5.7% 
  Missing    1,322  5.2%     287  3.4%     240  4.6%     417  7.5%      4,005  3.2%     5,950  2.2%     8,908  2.1%  34,764  3.7% 
  Mean      26.0  
 
   27.5  
 
   28.1  
 
   28.2  
 
      33.5  
 
      33.3  
 
      32.4  
 
     30.0    
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Smoking status at start   
       
  
      
  
  Current smoker    8,550  33.9%  2,636  31.7%  1,228  23.6%     758  13.6%    31,607  25.4%    63,722  23.4%    84,379  20.1% 107,723  11.5% 
  Ex-smoker    3,624  14.4%  1,612  19.4%  1,237  23.8%  1,639  29.5%    19,775  15.9%    57,182  21.0%  117,827  28.1% 337,839  36.0% 
  Non-smoker    1,291  5.1%     495  5.9%     366  7.0%     492  8.9%      4,818  3.9%    12,058  4.4%    23,330  5.6%  65,476  7.0% 
  Never smoked  10,958  43.4%  3,351  40.3%  2,207  42.4%  2,419  43.6%    65,531  52.6%  134,687  49.5%  187,495  44.7% 403,460  43.0% 
  Missing       829  3.3%     230  2.8%     166  3.2%     246  4.4%      2,817  2.3%     4,575  1.7%     6,828  1.6%  23,051  2.5% 
HbA1c, mmol/mol   
       
  
      
  
  First recorded (mean)      70.2  
 
   67.8  
 
   65.5  
 
   59.6  
 
      61.8  
 
      59.1  
 
      55.8  
 
     51.8    
Blood pressure   
       
  
      
  
  First recorded systolic 
(mean) 
   123.1  
 
 127.4  
 
 130.9  
 
 134.6  
 
     127.4  
 
    130.8  
 
    133.3  
 
   135.1    
  First recorded diastolic 
(mean) 
     75.1  
 
   77.8  
 
   77.5  
 
   75.0  
 
      79.9  
 
      80.6  
 
      79.4  
 
     75.3    
Cholesterol (mol/l)   
       
  
      
  
  First recorded (mean)       4.7  
 
     4.8  
 
     4.6  
 
     4.4  
 
        4.8  
 
        4.7  
 
        4.6  
 
      4.4    
eGFR   
       
  
      
  
  90+  14,774  58.5%  3,599  43.2%  1,605  30.8%     760  13.7%    76,887  61.7%  124,798  45.8%  133,190  31.7% 132,743  14.2% 
  60-89    5,598  22.2%  2,814  33.8%  2,112  40.6%  2,159  38.9%    29,220  23.5%    98,422  36.2%  189,553  45.1% 416,767  44.5% 
  30-59       213  0.8%     218  2.6%     352  6.8%  1,098  19.8%        920  0.7%     5,535  2.0%    22,064  5.3% 183,936  19.6% 
  15-29        23  0.1%       14  0.2%       26  0.5%       95  1.7%          89  0.1%        298  0.1%        774  0.2%    8,065  0.9% 
  <15          9  0.0%       15  0.2%       14  0.3%       29  0.5%          61  0.0%        151  0.1%        303  0.1%    1,084  0.1% 
  Missing    4,635  18.4%  1,664  20.0%  1,095  21.0%  1,413  25.4%    17,371  13.9%    43,020  15.8%    73,975  17.6% 194,954  20.8% 
 Deaths        559  2.2%     513  6.2%     508  9.8%  1,598  28.8%      1,836  1.5%      7,200  2.6%    22,315  5.3% 208,298  22.2% 
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Across the whole cohort having a diagnosis of Type 1 diabetes compared to Type 
2 diabetes was associated with a higher risk of mortality (HR 1.17, 95% CI 1.09-
1.26).  However, this association varied by age of diagnosis.  Amongst those 
diagnosed aged between 20 and 39 years old, having Type 1 diabetes rather than 
Type 2 diabetes is not associated with an additional risk of dying after adjusting 
for demographic characteristics and cardiovascular risk factors (HR 1.06, 95% CI 
0.94-1.19).  Type 1 diabetes rather than Type 2 diabetes is associated with 
higher mortality in those diagnosed aged 40 to 49 years old (HR 1.46, 95% CI 
1.33-1.61) and aged 50 to 59 years old (HR 1.22 95% CI 1.12-1.34).  The 
additional risk of dying associated with a diagnosis of Type 1 diabetes (compared 
to Type 2 diabetes) among people diagnosed aged 60 years and older is lower 
but still statistically significant (HR1.15 95% CI 1.09-1.21).   
If people with a diagnosis of Type 1 diabetes and a first recorded body mass 
index of 30kg/m2 or greater were excluded from the analysis the hazard ratio 
associated with a diagnosis of Type 1 diabetes changed to 0.91 remained not 
statistically significant (95% CI 0.78-1.05) in the 20-39 years age group.  All other 
results of the sensitivity analysis remained similar to the original model (see 
Table 7.2). 
Table 7.2: Sensitivity analysis – hazard ratios associated with Type 1 diabetes 
relative to those with Type 2 diabetes   
 
20-39 years 40-49 years 50-59 years 60+ years 
Base analysis 1.06 (0.94-1.19) 1.46 (1.33-1.61) 1.22 (1.12-1.34) 1.15 (1.09-1.21) 
T1 sensitivity 0.91 (0.78-1.05) 1.35 (1.20-1.52) 1.17 (1.04-1.31) 1.13 (1.06-1.21) 
T2 sensitivity 1.09 (0.95-1.25) 1.61 (1.45-1.78) 1.27 (1.15-1.40) 1.20 (1.13-1.26) 
T1 and T2 sensitivity 1.04 (0.83-1.22) 1.57 (1.39-1.78) 1.23 (1.09-1.39) 1.14 (1.06-1.22) 
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Figure 7.1: Hazard ratios associated with Type 1 diabetes by age of diagnosis 
relative to those with Type 2 diabetes   
 
 
Discussion 
This analysis has considered how the risk of medium term mortality compares 
between people with Type 1 and Type 2 diabetes.  Type 1 diabetes has 
traditionally been seen to have a larger detrimental impact on morbidity and 
mortality than Type 2 diabetes.  However, the results presented above show 
that when Type 2 diabetes is diagnosed between the ages of 20 and 39 years 
there is no significant difference after adjustment for demographic 
characteristics and cardiovascular risk factors.  This analysis suggests that 
diagnosis of Type 2 diabetes in early adulthood is equivalent to diagnosis of T1 
diabetes in terms of medium mortality risk.  An Australian study if 824 people 
diagnosed with diabetes between the ages of 15 and 30 years old found that 
those with Type 2 diabetes had a greater absolute and risk factor adjusted 
mortality rate than those diagnosed with Type 1 diabetes over a follow up period 
of over 20 years [120]. However this recruitment to this cohort dates back to 
1986 and there have been considerable shifts in the approach to managing 
diabetes, in particular Type 2 diabetes, over the follow up period which may 
explain the different findings to this analysis.  Another study in India reported 
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outcomes of 108 people with Type 1 diabetes and 90 with Type 2 diabetes 
diagnosed between the ages of 10 and 25 years after five years follow up.  After 
age, HbA1c, blood pressure and cholesterol those with Type 2 diabetes were 
approximately twice as likely to develop a diabetes related complication.  The 
small cohort size and very different patient characteristics and healthcare 
systems in England and India make it difficult to unpick the reasons for the 
potentially different outcomes in these studies.   
One of the strengths of this work is the large cohort size which reflects real 
world clinical practice and outcomes.  Everyone included in the analysis has 
been diagnosed with diabetes since 2008.  This means that they have been 
treated in the current paradigm of diabetes management for the duration of 
their condition.  The mean follow up period for this analysis was 5.8 years for 
those with Type 1 diabetes and 5.6 years for those with Type 2 diabetes.  A 
longer follow up period would provide further insight into the lifetime risks 
associated with a diagnosis of diabetes at various ages.  In particular, as those 
diagnosed in early adulthood move towards middle and later life their absolute 
risk of cardiovascular events and death will increase and the full impact of the 
potential association between age of diagnosis and outcomes will be clearer.   
The National Diabetes Audit is reliant on data recorded in clinical systems.  This 
includes the type of diabetes but this classification is dependent on accurate 
identification and recording.  Type of diabetes is usually verified by cross-
referencing with drug prescription data.  As the National Diabetes Audit does not 
currently collect this information, a sensitivity analysis based on the first body 
mass index measurement recorded after diagnosis was undertaken.  The fact this 
analysis did not substantially alter the study findings strengthens their validity. 
Is early diagnosis of Type 2 diabetes equivalent to diagnosis of Type 1 in terms of 
risk of dying?  This study appears to suggest that this is the case but further 
analysis over a longer time and considering a range of diabetes related outcomes 
is required to provide a more definitive answer.  Emerging evidence from 
Sweden suggests that those who develop Type 2 diabetes in adolescents lose 
well over a decade of life expectancy [123], which is on a par with Type 1 
development at the same age [124] using from data from same country.  These 
findings in NDA suggest that whilst excess risk declines with age of diagnosis in 
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Type 2 once people reach their 40s and older, it may be that such risks do not 
decline as much in people who develop Type 1 diabetes in their 40s and 
onwards, so explaining their higher risks in this age group.  Repeating these 
analyses once we have data for drugs prescribed as it may be that people 
diagnosed with Type 1 diabetes in middle age are not treated as aggressively as 
those developing Type 2 diabetes.  Certainly, some guidelines are less aggressive 
in their recommendations for preventative therapies [125] for this group than in 
those with Type 2 diabetes.  
Update 
A literature review conducted after the production of this chapter did not 
identify any further population based analyses comparing medium to long term 
outcomes among people with Type 1 and Type 2 diabetes.  As from 2017/18 
onwards the NDA includes data on prescriptions for glucose lowering drugs, anti-
hypertensive medications and statins there would be scope for future analyses to 
validate the classification of types of diabetes and consider how the 
management of cardiovascular risk factors mediates the additional risk of death 
experienced by those diagnosed with diabetes in early adulthood.  This would 
strengthen the methodology and potentially add to the understanding of 
mortality risk for those who live, or are likely to live, with diabetes for many 
decades.  In the meantime, it is clear that other national cohorts need to 
replicate our novel findings.  This work will be submitted for peer review in the 
near future.  
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Chapter 8: Age at diagnosis, ethnic group and mortality in people 
with Type 2 diabetes: Analysis of the National Diabetes Audit in 
England 
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Introduction 
 
Historically, Type 2 diabetes was considered a disease of middle to later life.  
Changes in lifestyle, particularly rises in obesity and physical inactivity, towards 
the end of the twentieth and at the beginning of the twenty-first century 
combined with an understanding that early diagnosis and management of Type 2 
diabetes can improve long term outcomes means that an increasing number of 
people are being diagnosed with the disease in early adulthood.   
 
A number of studies have found evidence of an additional risk of cardiovascular 
events or dying in people with Type 2 diabetes diagnosed in early adulthood 
compared to those diagnosed later in life [121,126,127].  However, relatively 
small cohort sizes and the inclusion of people diagnosed with diabetes prior to 
the big changes in management of Type 2 diabetes that followed the publication 
of trials in the late 1990s and early 2000s, specifically the impact of lower 
HbA1c and cardiovascular risk factor management (blood pressure and statins) in 
reducing complications and mortality.   
 
This analysis is able to assess whether there are associations between age at 
diagnosis of Type 2 diabetes and mortality in a large, representative and more 
contemporary ‘real world’ cohort. It looks at whether there are diagnostic age 
related differences in additional mortality and between ethnic groups In 
England.   
 
Methods 
 
The National Diabetes Audit combines data on people with diagnosed diabetes 
from primary and secondary care services.  This provides a database of patient 
characteristics (age, sex, ethnic group, social deprivation, smoking status).  For 
these people the National Diabetes Audit collates once each year the latest valid 
recorded measurement of HbA1c, blood pressure, total cholesterol, body mass 
index and eGFR in the 15 month period running from January to March the 
following year.  Using NHS numbers and year of birth people with Type 1 and 
Type 2 diabetes aged 20 years or older and recorded in the NDA as receiving care 
from an English NHS care provider after 1st January 2008 were matched to Office 
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for National Statistics death registrations up to 31st December 2015.  The earliest 
valid records of HbA1c, blood pressure, cholesterol, body mass index and eGFR 
were identified to give an indication of cardiovascular risk as close as possible to 
diagnosis. 
 
Statistical analyses  
The statistical significance of differences in the characteristics of people 
diagnosed with Type 1 and Type 2 diabetes by age of diagnosis was identified 
using chi-square tests for categorical variables.   
 
Cox regression models were created to explore the association between age at 
diagnosis and mortality after adjusting for  
• Age and sex 
• Age, sex and smoking status 
• Age, sex, smoking status, social deprivation as measured by the Indices of 
multiple Deprivation (IMD) and ethnic group 
• Age, sex, smoking status, social deprivation, ethnic group, duration of 
diabetes and HbA1c 
• Age, sex, smoking status, social deprivation, ethnic group, duration of 
diabetes and HbA1c, total cholesterol, diastolic and systolic blood 
pressure 
• Age, sex, smoking status, social deprivation, ethnic group, duration of 
diabetes and HbA1c, total cholesterol, diastolic and systolic blood 
pressure, body mass index and estimated glomerular filtration rate (eGFR) 
 
Diagnosis over the age of 60 years was used as a reference category.   
 
To assess whether the relationship between age of diagnosis and mortality risk 
varied by ethnic group separate models were created for people from white 
ethnic groups (White British, White Irish and White ‘other’ groups), from south 
Asian ethnic groups (Indian, Pakistani and Bangladeshi) and from Black ethnic 
groups (Black African and Black Caribbean).   
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Models were created to compare survival between people diagnosed at similar 
ages with Type 1 diabetes and Type 2 diabetes.  These models adjusted for age, 
sex, smoking status, social deprivation, ethnic group, duration of diabetes, 
HbA1c, total cholesterol, diastolic and systolic blood pressure, body mass index 
and estimated glomerular filtration rate (eGFR). 
 
Results 
 
The analysis included 1,754,180 people with Type 2 diabetes, of which 124,548 
(7.1%) were diagnosed between the ages of 20 and 39 years old.  The average 
follow up time was 5.6 years and there were 239,649 deaths. 
 
When compared with people diagnosed with Type 2 diabetes aged 60 years and 
older those diagnosed between the ages of 20 and 39 years old were less likely 
to be from White ethnic groups (48.6% vs 72.3%, p<0.005), more likely to live in 
the most deprived fifth of neighbourhoods (37.5% vs 26.7%, p<0.005), more likely 
to have a higher body mass index (mean 33.5 vs 26.0) and less likely to be a 
current smoker (25.4% vs 33.9%, p<0.005) (see Table 8.1).   
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Table 8.1: Characteristics by age of diagnosis of Type 2 diabetes 
 20-39 years 40-49 years 50-59 years 60+ years 
n % n % n % n % 
Total  124,548    272,224    419,859    937,549    
  Male 70,121  56.3% 166,128  61.0% 249,279  59.4% 487,545  52.0% 
Age at start of follow up           
  Mean(years) 35.4   46.5   56.2   72.1    
Ethnic group           
  White 60,543  48.6% 154,726  56.8% 268,468  63.9% 659,922  70.4% 
  South Asian 2,441  2.0% 4,119  1.5% 4,177  1.0%  5,347  0.6% 
  Black 27,586  22.1% 38,074  14.0% 40,740  9.7% 39,923  4.3% 
  Mixed 9,968  8.0% 19,392  7.1% 18,377  4.4% 25,969  2.8% 
  Other 10,180  8.2% 17,192  6.3%  19,899  4.7% 26,466  2.8% 
  Missing 13,830  11.1% 38,721  14.2% 68,198  16.2% 179,922  19.2% 
IMD           
  Most deprived 46,721  37.5% 85,754  31.5% 108,334  25.8% 188,934  20.2% 
  2nd most deprived 31,227  25.1% 64,415  23.7% 92,106  21.9% 189,626  20.2% 
  3rd most deprived 20,845  16.7% 49,240  18.1% 81,669  19.5% 197,441  21.1% 
  2nd least deprived 14,436  11.6% 39,352  14.5% 73,099  17.4% 191,634  20.4% 
  Least deprived 11,221  9.0% 33,313  12.2% 64,394  15.3% 169,179  18.0% 
  Missing 98  0.1% 150  0.1% 257  0.1% 735  0.1% 
Body mass index (kg/m2)           
  <18.5 418  0.3%  571  0.2% 920  0.2% 6,480  0.7% 
  18.5-24.9 11,753  9.4% 9,768  7.3% 31,605  7.5% 128,228  13.7% 
  25-29.9 30,102 24.2% 68,444  25.1% 118,484  28.2% 335,008  35.7% 
  30-34.9 31,057  24.9% 78,087  28.7% 130,650  31.1% 266,171  28.4% 
  35-39.9 22,742  18.3% 52,565  19.3% 75,242  17.9% 113,064  12.1% 
  40+ 24,471  19.6% 46,839  17.2% 54,050  12.9% 53,834  5.7% 
  Missing 4,005  3.2% 5,950  2.2%  8,908  2.1% 34,764  3.7% 
  Mean 33.5   33.3   32.4   30.0    
Smoking status at start           
  Current smoker 31,607  25.4% 63,722  23.4% 84,379  20.1% 107,723  11.5% 
  Ex-smoker 19,775  15.9% 57,182  21.0% 117,827  28.1% 337,839  36.0% 
  Non-smoker 4,818  3.9% 12,058  4.4% 23,330  5.6%  65,476  7.0% 
  Never smoked 65,531  52.6%  134,687  49.5% 187,495  44.7% 403,460  43.0% 
  Missing 2,817  2.3% 4,575  1.7% 6,828  1.6% 23,051  2.5% 
HbA1c, mmol/mol           
  First recorded (mean) 61.8   59.1   55.8   51.8    
Blood pressure (mmHg)           
  First recorded systolic 
(mean) 
127.4   130.8   133.3   135.1    
  First recorded diastolic 
(mean) 
79.9   80.6   79.4   75.3    
Cholesterol (mol/l)           
  First recorded (mean) 4.8   4.7    4.6   4.4    
eGFR           
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  90+ 76,887  61.7% 124,798  45.8% 133,190  31.7% 132,743  14.2% 
  60-89 29,220  23.5% 98,422  36.2% 189,553  45.1% 416,767  44.5% 
  30-59 920  0.7% 5,535  2.0% 22,064  5.3% 183,936  19.6% 
  15-29 89  0.1% 298  0.1% 774  0.2% 8,065  0.9% 
  <15 61  0.0% 151  0.1% 303  0.1% 1,084  0.1% 
  Missing 17,371  13.9% 43,020  15.8% 73,975  17.6% 194,954  20.8% 
Deaths 1,836  1.5% 7,200  2.6% 22,315  5.3% 208,298  22.2% 
 
Diagnosis of Type 2 diabetes between the ages of 20 and 39 years old compared 
to aged 60 years and over is associated with a hazard ratio of mortality of 2.23 
(95% CI 2.12-2.35, adjusted for age and sex) Figure 8.1. 
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Figure 8.1: Hazard ratios for mortality associated with age of diagnosis of Type 2 diabetes 
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Adjustment for demographic characteristics (social deprivation, ethnic group) 
and smoking status does not alter this association (HR 2.24, 95% CI 2.12-2.35).  
Further adjustment for duration of diagnosed diabetes and first recorded HbA1c 
reduces the additional risk of death (HR 2.00, 95% CI 1.90-2.11).  Extending the 
model to include all available risk factors (first recorded blood pressure, 
cholesterol, body mass index and eGFR) further attenuates the additional risk of 
dying associated with diagnosis in early adulthood (HR 1.40, 95% CI 1.33-1.47).  A 
significant but lower additional risk of mortality is found when those diagnosed 
aged 40 to 49 years old are compared to those diagnosed over the age of 60 (HR 
1.46, 95% CI 1.42-1.50 when adjusting for age and sex, HR 1.09, 95% CI 1.06-1.12 
when adjusting for all available risk factors).  When those diagnosed aged 
between 50 and 59 years old are compared to those diagnosed aged 60 and over 
there is an additional risk of dying after adjusting for age and sex(HR 1.13, 95% 
CI 1.11-1.15) but this is removed once adjustment includes cardiovascular risk 
factors (HR 0.99, 95% CI 0.97-1.01 when adjusting for all available risk factors).   
After adjustment for demographic characteristics (age, sex, social deprivation) 
and cardiovascular risk factors (smoking, duration of diabetes, HbA1c, blood 
pressure, cholesterol, body mass index and eGFR) younger age at diagnosis of 
Type 2 diabetes is associated with higher medium term mortality in those from 
White ethnic groups (see Table 8.2 and Figure 8.2).   
 
Table 8.2: Hazard ratios associated with age of diagnosis of Type 2 diabetes 
by ethnic group 
 White Asian Black 
HR (95% CI) HR (95% CI) HR (95% CI) 
Age at 
diagnosis 
<40 1.49 (1.40-1.59) 0.93 (0.78-1.21) 1.61 (1.23-2.11) 
49-49 1.13 (1.09-1.17) 0.99 (0.86-1.13) 1.12 (0.93-1.34) 
50-59 1.00 (0.98-1.02) 0.92 (0.84-1.02) 1.06 (0.93-1.21) 
60+ Reference group Reference group Reference group 
 
After adjustment for age, sex, smoking, social deprivation, ethnic group, 
duration, HbA1c, blood pressure, cholesterol, body mass index and eGFR 
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Figure 8.2: Hazard ratios associated with age of diagnosis of Type 2 diabetes by 
ethnic group 
 
When compared to diagnosis aged 60 years and older being diagnosed with Type 
2 diabetes between the aged of 20 and 39 years was associated with a higher risk 
of death after adjustment for demographic characteristics and cardiovascular 
risk factors (HR 1.61, 95% CI 1.23-2.11) in people from Black ethnic groups.  The 
additional risks of death associated with diagnosis of Type 2 diabetes between 
the ages of 40 to 49 and 50 to 59 years old compared to aged 60 years and older 
in people from Black ethnic groups were not statistically significant (see Table 
8.2 and Figure 8.2).  There was no statistically significant association between 
age of diagnosis of Type 2 diabetes and risk of mortality amongst those from 
South Asian ethnic groups (HR 0.97 for those diagnosed aged 20 to 39 years old 
compared to aged 60 years and older, 95% CI 0.78-1.12).   
 
Discussion 
 
The analysis of this large observational dataset has shown that diagnosis of Type 
2 diabetes in early adulthood is associated with a higher risk of dying over the 
medium term compared to diagnosis in later life.  Some of this additional risk of 
mortality is explained by the poorer cardiovascular risk profiles of people 
diagnosed at younger ages.  However, even after adjustment for established risk 
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factors the additional risk of dying remains considerable (HR 1.40, 95% CI 1.33-
1.47).  This supports the suggestion that Type 2 diabetes that develops in early 
adulthood is a different and more deadly phenotype than occurs in people who 
are diagnosed in later life.   
 
Some previous studies have provided tentative evidence of greater risks 
associated with Type 2 diabetes diagnosed in early adulthood.  An Australian 
study of 354 people diagnosed with Type 2 diabetes between the ages of 15 and 
29 years found they had mortality rates three times greater than the general 
population (SMR 3.4 95% CI 2.7-4.2).  They reported that as the age of diagnosis 
increased the additional risk of mortality in those with type 2 diabetes compared 
to the general population declined [121].  However, this study did not adjust for 
cardiovascular risk profile and covers those diagnosed from 1986 onwards and 
therefore covers a long period of time during which the approach to managing 
Type 2 diabetes has changed significantly.  This study showed that people 
diagnosed with Type 2 diabetes in early adulthood had a poorer cardiovascular 
risk profile than those diagnosed at older ages.  A recent analysis of over 
100,000 people with Type 2 diabetes in Sweden has also highlighted that those 
that were diagnosed at younger ages had a poorer cardiovascular risk profile 
(more frequently obese, more adverse lipid profile and a higher HbA1c).  It also 
reports that those diagnosed at a young age (aged 18 to 44 years) experienced a 
faster deterioration in glycemic control than those who developed diabetes later 
in life [127].   
 
This is perhaps the first study to consider how characteristics and outcomes in 
people with diabetes vary by age at diagnosis in different ethnic groups.  The 
association between younger age at diagnosis of Type 2 diabetes and a greater 
mortality risk is statistically and clinically significant for people from White and 
Black ethnic groups but no such association was found amongst those from South 
Asian ethnic groups.  This suggests that early diagnosis of Type 2 diabetes is not 
detrimental to mortality when compared to diagnosis in later life.  Previous 
studies have shown that South Asian people with Type 2 diabetes and in the 
general population have a lower risk of dying than their peers from White ethnic 
groups [128].  Further analysis over a longer time period would be required to 
explore this finding further and elucidate potential explanations for the 
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seemingly different risk of dying among people with Type 2 diabetes from South 
Asian groups.  In particular it would be useful to consider how trajectories of 
glycaemic control vary in different ethnic groups and potential interactions with 
other cardiovascular risk factors.   
 
The strength of this work lies in the large cohort of people included in the 
analysis and the fact that it represents a ‘real world’ setting collating data from 
routine clinical practice.  In particular, this has enabled the variation in risk by 
ethnic group to be considered.  It is also important to note that everyone 
included in this analysis has been diagnosed over a relatively short period during 
the current paradigm of diabetes management with a particular emphasis on 
intensive cardiovascular risk management in order to reduce current and future 
cardiovascular risk.   
 
This study is limited by the lack of data on prescribed medication.  It is also 
limited by lack of data on people without diabetes, as others have recently 
published [123] and showed similar higher excess risks in those diagnosed with 
Type 2 at younger ages.  It is possible that some of the additional risk of 
mortality shown in people who have been diagnosed with Type 2 diabetes in 
early adulthood can be explained by variation in the use of prescribed 
medication and the management of cardiovascular risk in this group.  Variation 
in either prescribing or drug efficacy by ethnic group should also be considered.  
The National Diabetes Audit has recently started to collect data on prescribed 
drugs and associated items [129].  In time, this will provide a valuable data 
source to examine further the high mortality risk experienced by those who 
develop Type 2 diabetes at relatively young ages.   
 
Whilst the follow up period for the cohort is reasonable, (mean 5.6 years), a 
longer follow up period would yield greater insight into difference in risk 
experienced depending on age at diagnosis.  In particular, it would be 
interesting to follow those diagnosed at younger ages as they proceed through 
middle and later life and consider their cardiovascular risk trajectories and 
morbidity.  As population and societal changes continue the increasing 
proportion of people with Type 2 diabetes who develop the disease in early 
adulthood is likely to increase, and clinicians are already starting to see more 
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and more people under 40 with newly diagnosed type 2 diabetes.  If these 
people continue to experience additional risks this is likely to result in greater 
need for health and social care over the coming decades.  Further research to 
understand these risks is crucial to inform potentially differing diabetes clinical 
management strategies and prioritisation of scare health care resources.   
 
Update 
Since the production of this chapter an analysis of the Australian National 
Diabetes Audit has reported that people with Type 2 diabetes under the age of 
64 showed poorer patterns of self-care (physical activity, following dietary 
recommendations, medication adherence and monitoring blood glucose levels) 
than those aged 64 and older. Within this cohort those in the younger age group 
also showed poorer glycemic control with 76% having a HbA1c of more than 
53mmol/mol compared to 68% in the older age group [130].  The role of 
individual self-care behaviors and the extent to which its full effect is captured 
by routinely monitored risk factors should be considered in explaining the higher 
medium term mortality amongst those diagnosed at younger ages noted in this 
chapter.  Our work needs replication in other national cohorts as it adds more 
questions than answers. That there is no clear gradient of cardiovascular risk by 
age of Type 2 diagnosis in South Asians is intriguing but we acknowledge this 
finding needs replication as well as an investigation into potential mechanisms if 
the findings are indeed validated by others.  
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Chapter 9: Discussion 
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This thesis is a collation of studies assessing current patterns of processes of 
care and outcomes for people in England with diabetes that have used data 
routinely collated as part of clinical care.  It provides a picture of the ‘real 
world’ outcomes for those with diabetes and highlights some of the 
methodological considerations when using data that has not been collected 
specifically for research purposes.   
The use of routinely collated data for research purposes creates an efficient way 
to consider outcomes for large cohorts of people.  It allows outcomes of ‘real 
world’ populations to be considered rather than the often highly selected 
cohorts included in specific research studies that tend to be younger, have fewer 
co-morbidities and potentially have a different approach to the management of 
their health to the complete group of people with diabetes.  Bespoke data 
collection on the scale required to create the study populations used in the 
analyses presented in this thesis would be costly and impractical. There is also a 
value in considering the actual and perceived ownership of data in how the 
results of research are presented to and received by clinicians working in 
diabetes care.  The presentation of the analysis of mortality among inpatients 
with diabetes (Chapter 3) to clinicians was initially met with criticisms of the 
dataset and methodology.  However, further discussion led to reflection and an 
understanding of the need to engage with routine data collection to ensure it 
accurately reflects clinical practice and outcomes.  
Despite the advantages, there are also drawbacks to the use of these type of 
data.  The accuracy and completeness of the data can be variable over time and 
place.  It can be subject to changes in definition or interpretation and may also 
be subject to organisational and financial incentives.  One of the challenges of 
using data originally collected for administrative purposes is not being able to 
define the data variables.  In Chapter 5 data on people presenting with diabetic 
foot ulcers in Salford are analysed.  This included data on four of the six 
dimensions of the externally validated and widely used SINBAD score.  As a 
result, the analysis used a measure of ulcer severity that was as close an 
approximation as possible.  Whilst this provides a useful measure of foot ulcer 
severity being able to use a validated tool and make more direct comparisons 
with other studies would have improved the interpretation of the results and 
allowed more meaningful discussion.  Similarly, the National Diabetes Audit 
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collates the latest valid result from clinical care processes in a 15-month audit 
period.  Chapters 7 and 8 consider a cohort of people with newly diagnosed 
diabetes and aimed to adjust for established cardiovascular risk factors.  An 
ideal analysis would assess and adjust for risk factors at the time of diagnosis 
but the nature of the data collection means that the earliest available 
measurements may be up to 15 months after this point.  Similarly validation of 
the type of diabetes recorded in the National Diabetes Audit was limited to cross 
referencing with body mass index measurements when linking to drug 
prescription data would have provided a more robust approach.  Despite the 
restrictions of data defined and collected for other purposes analysis can be 
useful in generating hypotheses although a pragmatic approach is often needed.   
This work has aimed to consider contemporary outcomes for people with 
diabetes.  Sometimes it is easiest to measure the process of healthcare (eg the 
number of procedures undertaken) rather than actual outcomes, in particular 
those that are most meaningful to patients.  This can be particularly true when 
using datasets whose primary purpose is administrative and financial.  Chapter 5 
reports the pilot work to develop a national data collection process and analysis 
plan for people with diabetic foot disease.  Much of the previous study in this 
area had used lower limb amputations as an outcome measure.  However, this a 
measure of treatment process and does not accurately capture the outcome of 
an episode of ill health from the perspective of the patient.  It was therefore a 
very deliberate decision to include a measure of quality of life in the data 
collection and this provided useful additional information on outcomes.  
Previous analysis of the National Diabetes Audit shows how current 
cardiovascular risk factors compare to those reported in the landmark studies 
undertaken at the end of the 20th century that shape the current approach to 
diabetes management [47].  The fact that the current population wide outcomes 
for people recently diagnosed with Type 2 diabetes are similar to those achieved 
amongst a highly selected group receiving intensive care as part of a research 
study is a considerable achievement.  The publication of the UKPDS study 
coincided with the first change in the national governing party in a generation.  
This lead to a paradigm shift in healthcare with a greater emphasis on 
preventative medicine and the proactive management of long-term conditions.  
However, over the next couple of decades the nature of diabetes care is likely to 
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change.  Current lifestyle trends towards inactivity and obesity in conjunction 
with demographic changes and improvements in mortality are leading to higher 
prevalence of Type 2 diabetes, in particular amongst younger adults.  Chapters 7 
and 8 explored the variation in mortality by age of diagnosis and supported 
previous studies that have highlighted the poor outcomes associated with the 
diagnosis of Type 2 diabetes in early adulthood.  However, the suggestion that 
there are significant differences in this association between ethnic groups 
requires further investigation.  Even so, the rising number of diabetes patients 
at both ends of the age scale, and particularly those who are younger and more 
obese, poses great challenges over the next few decades in the UK.  This means 
that primary and secondary prevention will increasingly be the way to improve 
outcomes and minimise the societal and financial costs of diabetes.  
Furthermore, rising prevalence of diabetes and its complications in low and 
middle-income countries due to changes in lifestyle will lead to major human 
and financial challenges for societies throughout the world.  
 
Going forwards 
Given my knowledge of the epidemiology of diabetes and experience in analysing 
the NDA, I have been fortunate to win further funding from Diabetes UK to run 
additional analyses on this cohort. This will include working in conjunction with 
an advisory group of clinicians with relevant clinical and epidemiological 
expertise, including some of my supervisors for my thesis.  Whilst not a 
comprehensive list, some of the further analyses I will purse include the 
following:  
1. I have begun to look at number of people who may have undergone 
remission of Type 2 diabetes.  This is a complex analysis which makes use 
of the newly collated drugs data.  It is of great importance given the 
recent results of the DIRECT trial [131] as well as an increasing focus on 
lifestyle changes that are taking place in the National Diabetes Prevention 
Programme.  
 
2. There is increasing interest in heart failure and to this end, we have a 
potential to look at how common heart failure is, trends in incidence and 
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potential changes in the association between risk factors over time in 
people with diabetes.  We will also look at the commonest first vascular 
presentation in diabetes patients without prior cardiovascular disease to 
see if we can verify that heart failure and peripheral vascular disease are 
becoming more common first presentations, as suggested by a recent 
seminal report based on two million patients [132].   
 
3. As data on prescriptions for glucose lowering, anti-hypertensive and statin 
drugs are becoming available through the NDA the scope of analysis will 
expand. There will be potential to undertake pharmacoepidemiological 
analyses which will have great statistical power given the large size of the 
NDA which is substantially bigger than Scottish, Swedish or indeed many 
other datasets with similar level of linkage.  Of course, longer follow-up 
will be needed to enable sufficient follow up to look at outcomes as these 
numbers increase over time from the point when drug data became 
available and the impact of exposure over time becomes identifiable.  In 
the meantime, we can have the ability to examine patterns of drug 
prescription, which has assumed greater importance given the rise in the 
use of newer diabetes drugs in the SGLT2i and GLP-1RA classes.  
 
4. There will be multiple other ideas to pursue and there is also the 
potential to collaborate with other national datasets in analyses that are 
mutually beneficial.  For example, my supervisors have links to Swedish, 
Danish and Scottish Registries and in some cases, there is a need to 
replicate findings in other countries to confirm patterns.   
 
Overall, I am confident that with the knowledge I have accumulated working on 
this thesis, including all the obstacles we had to overcome, as well as all the 
links I have made, I am ideally placed to make a meaningful contribution to 
future diabetes care epidemiology.   
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